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PCR based diagnosis of micrometastatic and
residual cancer
P Selby
ICRF Cancer Medicine Research Unit, St James's University Hospital,
Leeds LS9 7TF
PCR has provided an opportunity to detect small quantities of
cancer cells. This has been applied to the detection of micro-
metastatic and microresidual cancers in the blood and bone
marrow. Haematological cancers may present consistent abnor-
malities of DNA with characteristic translocations which provide
targets for detection. Successful detection of micrometastatic
disease using these approaches is now common for several haema-
tological cancers although the complexities ofinterpretation ofthe
data must be emphasised. Technical problems are common and the
extreme sensitivity of the technique may reveal translocations to
be present at a low level in normal tissues. Solid tumours represent
a greater technological challenge. Specific abnormalities of DNA
are less well described. An alternative approach has been to detect
the expression of genes which are specific to the tissue oforigin of
a cancer but are not normally expressed in the tissue under study
for the presence ofmicrometastatic disease, usually blood or bone
marrow. This approach has proved promising for a number of
cancers, particularly melanoma, neuroblastoma, prostatic cancer,
with some less certain success for breast and colorectal cancer.
The clinical situations where useful information may be found
include the detection ofmicrometastatic disease as part ofstaging,
during and after treatment in follow-up and the detection of con-
tamination of peripheral blood stem cell harvests. Data suggest
that we should investigate the role ofthese techniques but the tech-
nical challenges are considerable and comparisons between inter-
ested laboratories have shown a persisting difficulty with false
positive and negative tests.
Minimal residual disease in solid cancer:
chance and challenge for new diagnostic and
therapeutic strategies
G Riethmuller
Institute of Immunology, University of Munich, D-80336, Munich
Despite progress in early diagnosis metastasis frequently precedes
detection of primary tumours in patients with the most common
types ofepithelial cancer. Thus, systemic and occultdissemination
of cancer cells accounts for a sizeable proportion of cancer
mortality in the Western industrialized countries. Recent advances
in immunological and molecularbiological techniques have made
possible the detection of isolated disseminated tumour cells. In
various tumours, the presence of such cells in bone marrow has
been shown to have prognostic significance for the clinical devel-
opment of the disease, i.e. for a manifest relapse at distant sites.
Because of their relatively low number and accessible location in
mesenchymal compartments isolated metastatic cells are ideal
targets for new biological or immunological therapeutic strategies.
Immunotherapies relying on cooperative activities with the
patient's immune system appear particularly attractive in the early
stage of minimal residual disease (MRD). Diagnostic and thera-
peutic data on MRD of various solid tumours will be presented in
my presentation.
Solid phase separation techniques have a
role in the detection of rare tumour cells in
either peripheral blood or bone marrow
JTKemshead
Oncology Laboratories, Frenchay Hospital, Bristol BS16 1LE
Conflicting claims have been made in the literature regarding the
level at which tumour cells can be detected inperipheral blood and
bone marrow by either immunological or molecular techniques.
Our experience with respect to the detection of neuroblasts in
blood products will be reviewed, with particular relevance to the
routine use ofthese procedures in a clinical setting. However, irre-
spective of the methodology, the sensitivity of tumour cell detec-
tion is limited by the volume of the sample which can be
processed. This limitation can be avoided if a pre-enrichment
procedure is used to partially enrich the tumour population. A
strategy to develop a solid phase separation procedure where rare
tumour cells can be isolated onto a solid phase matrix and subse-
quently released will be discussed. This technology is based upon
the use ofan immunomagnetic colloid and genetically engineered
antibodies.
Despite the advances made in detecting metastatic tumour cells
in blood and bone marrow, the clinical relevance of this work is
hotly debated. Using gene marking techniques it has been demon-
strated that, in children with neuroblastoma, contaminated blood
products can contribute to the relapse of patients. These studies
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have been undertaken in children receiving autologous marrow as
a rescue procedure after high dose consolidation therapy. This data
proves that such grafts should be subjected to 'purging techniques'
to ensure that they are free oftumour cells. However, some groups
still procrastinate about the use ofthis technology as they argue it
is unnecessary until consolidation therapies become more effec-
tive. Other centres continue to the drive to ensure that the tumour
burden is reduced to a minimum and consequently pursue the
development of highly sensitive purging techniques. We have
piloted such a procedure whereby CD34 positive cells are initially
isolated from either bone marrow or peripheral blood stem cell
grafts. This population is then subjected to a 'tumour purge' using
a cocktail of monoclonal antibodies and a solid phase separation
technique. Calculations indicate that this procedure can essentially
remove all tumour cells from either marrow or peripheral blood
stem cell harvests and experimental data confirms both its sensi-
tivity and safety.
Minimal residual disease in the leukaemias
John M Goldman
Haematology Department, Royal Postgraduate Medical School, London, UK
Residual leukaemia after treatment has in the past been defined at
the morphological or cytogenetic levels. In the last five years
molecular methods, especially RT-PCR, have been developed and
tested in patients in seeming complete remission after treatment for
acute and chronic leukaemias. Chronic myeloid leukaemia (CML)
is probably the prototypic disease in which RT-PCR for BCR-ABL
transcripts has proved clinically useful. CML patients treated by
allogeneic BMT with unmanipulated donor marrow often have
molecular evidence of residual disease for 6-9 months post-trans-
plant but this may disappear thereafter; conversely, patients who
receive T-depleted donor marrow may remain PCR-positive for
long periods post-BMT. Relapse may be defined on the basis of
rising numbers or persistently high numbers of transcripts more
than 9 months post-BMT and is presumably due to relative
failure of aGVL effect. Treatment may be instituted with low doses
of donor lymphocytes which re-induce remission in 70-80% of
cases. CML patients treated with interferon-a who achieve
complete cytogenetic remission remain PCR-positive with rare
exceptions but the numbers oftranscripts in different patients spans
4 orders of magnitude. Ph-negative 'high' PCR-positive patients
may be candidates forauto-harvesting and autotransplants in remis-
sion; 'low' PCR-positive patients include some who may be
regarded as operationally 'cured' and may need only 'observation'.
The pattern is somewhat less clearcut in AML. AML-M3 is charac-
terised by a PML-RARa fusion gene. Detection ofthe transcript in
chemotherapy-treated patients is associated with a high risk of
relapse, whereas PCR-negative patients have a low risk of relapse.
The sensitivity ofthe assay may be increased by studying the reci-
procal fusion transcript, RARa-PML. Conversely, AML patients
with t(8;21) have a chimeric mRNA for the AMLI-ETO fusion
gene but its detection in remission does not predict relapse. This
suggests that this fusion gene may not be the sole pathogenetic
mechanism operating in this sub-type of leukaemia. Preliminary
data also suggest that detection of the chimeric transcript for the
CBFf-MYH11 fusion gene characteristic of AML with inv[16]
also correlates poorly with the risk of relapse. Residual disease
after treatment for ALL may be monitored by specific chimeric
transcripts orclonal rearrangements ofIGH orTCR genes; a poten-
tially valuable approach is based on the observation that 20-25% of
children with ALL have a TEL-AMLI fusion gene; corresponding
transcripts are undetectable after treatment in some patients. In
summary, molecular methods forfollowing patients with leukaemia
in apparent remission seem to be ofincreasing value and will in the
coming decade constitute an important basis for 'tailored' therapy.
Genetics of the malignant progression of
human brain tumours
WCavenee
Ludwig Institute for Cancer Research, Dept. of Medicine and Center for
Molecular Genetics, Univ. California-San Diego, La Jolla 92093-0660
One model for the malignant progression exhibited by human
cancer invokes clonal evolution and selection ofpopulation subsets
with increasing deviance from the norm. We have beenparticularly
interested in the suitability ofthe model to astrocytic brain cancer.
Low grade glial tumours are distinguished phenotypically from
normal brain by their greater degree of cellularity, nuclear atypia
and increased microvessel density. From a genetic standpoint,
mutation of the p53 gene is the earliest detectable genetic lesion
and by analysing its mutations in low grade and corresponding
recurrent high grade tumours, direct support has been derived for
the clonal evolution model. Wild-type p53 but not common tumour
mutants causes cessation of growth following dramatic morpho-
logical changes. Thus, the cell number and shape changes seen in
low grade disease may be attributable to this early genetic lesion.
Further evidence was obtained by deriving cultures of primary
cortical astrocytes from mice whose endogenous p53 alleles were
genetically 'knocked out'. These studies showed that immortaliza-
tion was conferred by p53 allele inactivation and that this process
engendered an increased probability of cell transformation. Wild-
type p53, but not its commonly occurring mutant forms, caused
glioma cells to secrete an inhibitor active in limiting both endothe-
lial cell migration and neovascularization. This inhibitor neutral-
ized the positive angiogenic factors secreted by the tumour cells,
such as bFGF or VEGF. In the case ofthe latter factor, expression
ofantisense constructs resulted in ablation oftumourigenicity.
Finally, we have identified additional genetic lesions in high
grade disease. These include alterations in one component or
another ofthe pl6/CDK4/CDK6/RB complex required for control
of the GI cell cycle checkpoint as well as truncation and amplifi-
cation ofthe EGF receptor. In the latter case, molecular dissection
ofthe signal transduction pathways has led to the identification of
a specific inhibitor which may be useful as an adjunct to tradi-
tional therapies.
Identification of initiating genetic events in
human neoplasia
D Wynford-Thomas
Dept. Pathology, UWCM, Cardiff, UK
Although most human tumours can now be associated with
multiple somatic mutations, identifying the key initial event is still
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problematic. Presence of the genetic abnormality in the earliest
recognisable tumour stage is a necessary criterion (and sometimes
crucial in preventing misleading extrapolation from experimental
models) but even in 'multi-stage' tumours can never exclude prior
cryptic events. Proof of causality depends on demonstration that
the genetic lesion is sufficient to induce an experimental analogue
of the early tumour phenotype, for which the most popular
approach is to use tissue-specific expression in a transgenic
mouse. While this is undoubtedly a valuable model for familial
cancers, expression of a mutant gene in all cells of a tissue and
from an early developmental stage is a poor model of somatic
mutation arising in a single adult cell, and not surprisingly can
generate misleading pathologies, particularly with activated onco-
genes. Our laboratory has used the complementary approach of
gene transfer into normal epithelial cells in vitro, which allows use
of human cells (although of course has limitations imposed by
tissue culture). Using amphotropic retroviral vectors the earliest
stages in development of tumours of the thyroid follicular cell
were successfully reconstructed, and provided strong evidence that
the resulting phenotype ('follicular' or 'papillary') is determined
by the 'choice' ofinitiating oncogene (ras or retrespectively), thus
providing a molecular explanation for the occurrence ofdivergent
tumour pathologies from a common cell oforigin. This model has
also been exploited to develop novel approaches to early therapy
or prevention, based on targetting the signal pathways ofthe initi-
ating oncogene. Although the picture is still incomplete, transgenic
and gene transfer models of different tumour types are beginning
to reveal relationships between the nature of the initiating event
and the cell kinetics of the normal tissue, e.g. activation of onco-
genes in mitotically-inactive thyroid, contrasting with inactivation
of a tumour suppressor gene in renewing epithelium of colon.
Such data may provide new insights into the tissue-specific rate-
limiting controls ofnormal cell proliferation.
Genetic control of tumour predisposition and
progression in mice
A Balmain
CRC Beatson Laboratories, Department of Medical Oncology, University of
Glasgow, Garscube Estate, Bearsden, Glasgow G61 1BD
Tumours develop in both mice and humans as a consequence of
several genetic alterations at critical genomic loci. These changes
involve mutations in oncogenes such as ras, and in tumour
suppressor loci, including the p53 and p16 genes. Our strategy has
been to investigate the genetic alterations which take place during
mouse skin tumour development, and subsequently to use both
transgenic and knock-out mice to test the functions of candidate
genes in vivo. Genes implicated in multistage carcinogenesis
include H-ras, p53 and TGF,. We have generated transgenic lines
expressing H-ras and TGF, in specific subpopulations of
epidermal cells using keratin gene promoters. These animals show
alterations in epidermal growth and differentiation and in their
susceptibility to tumour development. Mice expressing TGF3
develop fewer papillomas than non-transgenic littermates, but
have elevated rates of tumour progression. This indicates that
TGFP can act either positively or negatively at different stages of
carcinogenesis. The p53 tumour suppressor gene plays a critical
role in prevention of tumour progression, by mediating apoptosis
in response to accumulating genetic damage. Mice deficient in p53
show reduced apoptosis, and consequently an increased progres-
sion frequency.
Another class ofgenes which are important in tumour develop-
ment are those which control genetic predisposition. Different
mouse strains have differing susceptibilities to develop either
benign or malignant tumours, and several ofthese genes have been
mapped in crosses between sensitive and resistant strains. Many of
these germline predisposition loci show alterations in somatic cells
during tumour progression, suggesting that they act as bona fide
tumour suppressor genes.
The identification and characterisation of
BRCA2
M Stratton
Section of Molecular Carcinogenesis, Institute of Cancer Research, Sutton,
Surrey SM2 5NG
The breast cancer susceptibility gene, BRCA1, was located on
chromosome 17q in 1990. Subsequently an analysis of over 200
families with multiple cases of breast cancer suggested that
although the large majority of families with both breast and
ovarian cancer are due to this gene, only 50% of families with site
specific breast cancer are due to BRCA1. The existence of a
further susceptibility gene was confirmed by an analysis of fami-
lies with at least one case of male breast cancer (and usually
several ofearly onset female breast cancer), most ofwhich appear
not to be due to BRCA1. A genome search resulted in the localisa-
tion ofBRCA2 to chromosome 13ql2-ql3 in 1994.
Evidence from breast cancers arising in mutation carriers
provided evidence that BRCA2 is a tumour suppressor gene and
loss ofheterozygosity on chromosome 13q was found in approxi-
mately one third of sporadic breast cancers. BRCA2 was isolated
in 1995 by positional cloning. The gene encodes a large predicted
protein of 3,318 amino acids that bears no substantial sequence
similarity to other proteins in the publicly accessible databases
although there is an eight times repeated 25 amino acid motifofan
unknown function. Germline mutations in BRCA2 usually result
in truncation ofthe protein and hence likely inactivation ofcritical
functions. Somatic mutations of BRCA2 in sporadic breast or
ovarian cancers have not been found. Mutations in BRCA2 are
now believed to result in an excess risk of ovarian cancer,
leukaemia, prostate cancer, pancreatic cancer, and endometrial
cancer in addition to male and female breast cancer.
Genetic analysis of early breast lesions
JM Varley, KMarsh, KMunn andL James
CRC Department of Cancer Genetics, Paterson Institute for Cancer
Research, Wilmslow Road, Manchester M20 9BX
Ductal carcinoma in situ of the breast (DCIS) is considered by
many to be apreinvasive precursorto frankly invasive tumours. We
have analysed a number of cases of DCIS which are either 'pure'
DCIS or associated with invasive tumours, for LOH at a number of
chromosomal loci. For the analysis, multiple independent ducts are
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microdissected from formalin-fixed, paraffin-embedded sections,
and each duct is analysed separately. Ifpresent, regions ofinvasive
carcinoma are similarly prepared from the same section. In all
cases sections ofnormal breast are available as a control. We have
concentrated on regions ofthe genome known to show high levels
ofLOH in invasive tumours, including regions ofchromosomes 1,
9 and 17. All these regions show loss at levels which are compa-
rable to those seen in invasive tumours, and furthermore are
present in well-differentiated lesions as well as poorly-differenti-
ated DCIS. We have seen considerable levels of heterogeneity
between ducts of the same subtype, as well as between ducts of
different subtypes.
Comparative genome hybridisation (CGH) is a technique which
allows the genome-wide examination of regions of chromosomal
loss or gain using techniques offluorescence in situ hybridisation.
A number of cases of DCIS have been analysed using this tech-
nique, after microdissection and pooling of multiple lesions from
the same patient. A wide variety of abnormalities were detected,
including gain and loss ofmaterial, and high-level amplification of
some areas was also observed. Chromosomal alterations are more
frequent in higher grade DCIS, and closely resemble those previ-
ously detected in invasive breast cancer using the same technique.
Taken together, ourdata indicate that most, ifnotall, the genetic
alterations seen in invasive breast tumours are present in DCIS.
We have seen loss and gain of sequences in lesions of all grades
and degrees of differentiation, although the changes are more
numerous and more frequent in DCIS lesions of high nuclear
grade and poor differentiation.
Genetic events in the development and
progression of bladder cancer
MargaretA Knowles
Molecular Genetics Laboratory, Marie Curie Research Institute, The Chart,
Oxted, Surrey RH8 OTL
Bladder cancer is a heterogeneous disease. Two major groups of
tumours exist (superficial papillary and invasive) with very
different clinical outcome. It is anticipated that a detailed know-
ledge of the molecular genetics of these lesions will provide a
basis for understanding this divergent clinical behaviour and
should generate useful tools for diagnosis, prediction ofprognosis
and ultimately for therapeutic intervention.
Many common genetic changes have been identified in transi-
tional cell carcinoma (TCC) of the bladder. These include alter-
ations to proto-oncogenes (HRAS, ERBB2 and CCND1),
mutation or homozygous deletion of tumour suppressor genes
(TP53, RB1 and CDKN2 [pl6]) and frequent loss of heterozy-
gosity (LOH) of chromosome arms 3p, 4p, 4q, 8p, 9q, llp, llq
and 14q. Detailed mapping and positional cloning projects are
underway to identify candidate genes within regions of frequent
LOH, particularly those on the long arm of chromosome 9 which
is deleted in the majority of bladder tumours of all grades and
stages. We have mapped the common regions ofLOH on chromo-
somes 4p, 8p and 9q in detail. Two critical regions on 4p, at least 2
regions on 8p and 3 regions on 9q have been defined. Precise
localisation for two putative target loci have been obtained and
analysis ofcandidate genes from these regions will be presented.
Until recently, the natural history of development of papillary
and invasive TCC was not well defined. Molecular genetic find-
ings now indicate that two major pathways of progression exist,
one via carcinoma in situ ->invasive TCC, the other via hyper-
plasia ->dysplasia->papillary TCC. The temporal ordering of
events in these pathways is not clear though LOH ofchromosome
9 is considered a likely 'early' event. Thus, identification of the
relevant tumour suppressor genes on chromosome 9 is considered
pivotal to progress in understanding the development and clinical
behaviour ofTCC.
Heparan sulphate and the development of
oligosaccharide growth factor inhibitors
GCJayson1, C Paraskeva2, JTGallagher'
'CRC Dept. of Medical Oncology, Paterson Institute for Cancer Research,
Withington, Manchester M20 4BX. 2Dept. CRC Colorectal tumour biology
group, Dept. Pathology and Microbiology, Univ. of Bristol, Bristol BS8 lTD
Heparan sulphate (HS) is awidespread, complex, linear, cell surface
and extracellular matrix glycosaminoglycan that is of fundamental
importance in the control ofcell growth. HS is ofincreasing clinical
interest because it acts in a catalytic fashion to increase the binding
and activation of a number of growth factors, including FGF-1, -2,
-4, VEGF and hepatocyte growth factor (HGF). These observations
have focused attention on HS as a target for new anti-cancer strate-
gies. To determine the optimum method of targeting HS we
analysed the structure ofHS derived from the first in vitro model of
the progression from human adenoma to carcinoma. The transition
to a carcinomatous phenotype was associated with a 50% reduction
in the synthesis ofHS relative to CS and a significant reduction of
syndecan 1 and 4 mRNA. In HS specific structural changes were
seen during progression, including a 17% reduction in total sulpha-
tion, a 22% reduction in N-sulphation, a 50% reduction in 2-0-
sulphation and a 17% increase in 6-O-sulphation. The chains were
trisected by two sulphated domains that were larger in the adenoma
HS. On average an adenoma HS chain contained 2 mono- and 3 di-
sulphated nitrous acid resistant tetrasaccharides, while a carcinoma
HS chain contained 1 mono-, 2 di- and 1 tri-sulphated nitrous acid
resistant tetrasaccharides.
Basic FGF was an effective mitogen forthe adenomacells(EC50
= 1 ng/ml) but not for the carcinoma cells, yet RT-PCR techniques
detected the same classes ofFGF-R in the adenoma and carcinoma
cells. Investigation of the relationship between adenoma HS and
bFGF and carcinoma HS and bFGF showed that progression is
associated with a change in dissociation constant from 220 nM to
2493 nM, suggesting that HS may in part control the cells'
response to bFGF.
HS undergoes specific structural and functional changes during
progression, implying that it is a potential target for new anti-
cancer strategies. In further experiments Caco-2, a human colon
carcinoma cell line, was adapted to growth in serum free medium.
This model responds to bFGF with an increase in cell multiplica-
tion and movement and the mitogenic effect ofbFGF is dependent
on HS. The ability ofheparin oligosaccharides ofdifferent lengths
but uniform composition to inhibit these activities was tested. This
showed that the optimum length of an inhibitory oligosaccharide
was an octasaccharide which caused asignificant reduction in both
bFGF induced mitogenesis and motility at l0jg/ml, a clinically
achievable concentration.
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Histotypes, clonality and cytotoxic molecules
in Hodgkin's disease
H Stein, MHummel, TMarafioti, H-D Foss
Institute of Pathology, University Hospital Benjamin Franklin, Freie
Universitat, 12200 Berlin, Germany
By the demonstration ofa constantexpression ofthe lymphoid cell
activation associated cytokine receptor CD30 and an occasional
expression ofB- orT-cell antigens on Reed-Stemnberg cells we had
provided growing evidence suggesting that Hodgkin's disease can
be B-cell related orT-cell related. To furtherelucidate this issue we
and others analysed single Reed-Stemnberg cells for rearranged Ig
variable (V) genes and cytotoxic molecules (granzyme B and
perforin). For the detection of IgV rearrangements single Reed-
Stemnberg cells were isolated from frozen sections that had been
immunostained for CD30 and analysed by PCR followed by
sequencing. The cytotoxic molecules were either demonstrated by
immunohistology (granzyme B) or by in-situ hybridization
(perforin). Using various primer sets we found identical IgV
rearrangements in Reed-Stemnberg cells in eight and unrelated IgV
rearrangements in two often B-cell immunophenotyped HD cases.
Cytotoxic molecules were demonstrated in Hodgkin's disease with
a T-cell or null-cell immunophenotype accounting for 10-20% of
all Hodgkin's disease cases. These findings confirm the existence
of Hodgkin's disease cases with B-cell derived Reed-Stemnberg
cells and Hodgkin's disease cases with T-cell derived Reed-
Stemnberg cells. An EBV infection could be demonstrated in both
B-type and T-type Reed-Stemnberg cells.
Prognostic factors in cancer: myths,
mistakes, and the Holy Grail
PeterA Halil andNellA ShepherdP
'Dept of Molecular and Cellular Pathology, University of Dundee DD1 9SY
and 2Dept of Cellular Pathology, Gloucestershire Royal Hospital,
Gloucester GL1 3NN
The search for parameters that might facilitate the prediction of
patient outcome is a highly prevalent activity in oncology: indeed
it represents a form ofHoly Grail. During the period from January
1993 to July 1996, 2531 publications are listed by BIDS as having
the term prognosis in the title and 16 078 with the same word in
title and abstract. Examination of an unselected series of these
publications in mainstream oncology, pathology orgeneralistjour-
nals indicate that many studies are methodologically flawed,
frequently being based upon small numbers of patients (with
consequent small power) and being poorly controlled. The use of
more than one data set is vanishingly rare. Prospective studies to
test analyses do not predominate and the phrase '... this parameter
may be of prognostic significance' is sadly common. The cut-off
points employed are rarely validated and often have no clearly
defined biological rationale. While a significant subset of studies
endeavour to employ multi-parameter (usually Cox) modelling
many fail to make comparisons with commonly used and well
established prognostic parameters. Most studies are performed in
the context of tertiary referral or other specialist centres and the
applicability ofresults to the 'real' world is not often clear.
While there is no question that the aims are valid and worth-
while this paper presents a critical analysis of prognostic studies
and urges the use of more rigorous and scientific approaches
including the application of multiple data sets, the use of fully
unselected series, the experimental testing ofcut-offpoints and the
more realistic consideration of the long term practicability of
methods in real clinical settings.
The tumour suppressor gene p53 as a
predictive factor in human breast cancer
JBergh
Dept of Oncology, Univ. of Uppsala, Akademiska sjukhuset, S-751 85
Uppsala, Sweden
Introduction: p53 is the conductor for many essential cellular
processes, e.g. control of proliferation, differentiation and apop-
tosis. The gene is localised to band 13.1 on the short arm of chro-
mosome 17. The protein consists of 393 amino acids with a DNA
binding region between amino acids 102 and 292. Preclinical
studies have demonstrated that certain cytostatics, tamoxifen and
radiation may induce programmed cell death via the p53 pathway.
Previous clinical studies have revealed prognostic importance for
p53 for a wide range ofmalignant tumours. Based on these obser-
vations we started to investigate different aspects of p53, mainly
with focus on its eventual predictive value in relation to used onco-
logical therapies for breast cancer.
Material and methods: Weisolated tumourcDNA and sequenced
all exons from p53 obtained from a population and consecutive
cohort of 316 breast cancer patients operated between 1987 to
1989. We also studied immunohistochemical determination ofp53
using the monoclonal antibody Pab 1801 compared with
sequencing. We have a median follow-up of 57 months and a
maximum of87 months.
Results: 69 mutations were found, 29 in the node positive group.
The mutation sites werepartly dissimilar between the node positive
and node negative group. Node positive patients tended to have
relatively more mutations within the evolutionary conserved
regions II and V which was associated with very grim prognosis.
Lymph node positive patients with p53 mutations treated with
loco-regional radiotherapy and tamoxifen had a significantly worse
prognosis compared with those without p53 mutations. Vice versa,
lymph node negative patients with p53 mutations postoperatively
treated with radiotherapy had a significant survival benefit while
those patients without p53 mutations had no major effect on local
recurrence and survival. The discriminatory clinical findings
between the node positive andnegative patients with respect top53
may be due to different mutation sites leading to dissimilar func-
tional implications for the p53 protein. The prognostic information
was better using sequencing and immunohistochemistry failed to
detect all 6 stop codons, 11/13 deletions and 1/3 insertions.
Conclusion: Ourstudies strongly indicatethepredictive valueofp53
in relation to different adjuvant therapy modalities with different
implications for node positive and negative breast cancer patients,
which may be related to partly different sites ofthe mutations.
REFERENCES
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Molecular analysis and prognosis in
colorectal tumours
AH Wyllie, VJ Bubb, RG Morris, L Curtis, M Potter,
SirAlastair Currie
CRC Labs., Dept. of Pathology, University Medical School,
Edinburgh EH8 9AG
Molecular analysis of human colorectal carcinomas reveals two
major sub-types. In the first, there is defective p53 function
throughout the carcinoma, apparently involving the founder cells
of the malignant clone. Carcinomas of this sub-type - which is
responsible for around 70% of all colorectal cancers - have aneu-
ploid karyotypes and are associated with multiple chromosome
deletions and amplifications. The second major sub-type (respon-
sible for around 15% of all) is characterised by micro-satellite
instability, probably arising through deficient mis-match repair
functions. These tumours are usually near-diploid, tend to be right-
sided, commonly display mucinous or poorly differentiated
histology and have a conspicuously better prognosis than tumours
ofthe first sub-type. A small number of cancers appear to possess
qualities intermediate between these sub-types. The questions
arise whether these malignant tumours evolve from pre-existing
adenomas by similar or different pathways, and whether patients
bearing such tumours can be recognised at an early stage.
The role of p53 and related mediators and
effectors of p53 function in the molecular
pathology and prognosis of cancer
J Lunec
Cancer Research Unit, Univ of Newcastle upon Tyne
Medical School, NE2 4HH
The p53 tumour supressor gene is frequently found to be mutated
in a wide range of common sporadic tumours. Gene transfer in
vitro and in vivo as well as germline inactivation of the p53 gene
in mice have established clear causal links for the tumour
suppressor role ofp53. The p53 gene encodes a nuclear phospho-
protein that binds to DNA in a sequence specific manner and acts
as a transcription factor for the regulation of genes that play key
roles in cell cycle progression and in the response ofcells to DNA
damage. The cellular levels of p53 protein accumulate rapidly in
response to DNA damage and other cellular stresses. Ifthe p53 is
normal, this leads to either growth arrest or apoptotic death,
depending on the cell type and the level ofdamage. Thus the func-
tional p53 status ofcells is likely to be an important determinant of
tumour progression and response to treatment. The role ofp53 and
potential prognostic significance will be illustrated by data on
bladder and ovarian carcinoma and contrasted with the different
behaviour in childhood neural tumours.
Mutations ofthe p53 gene appear to be a late step in the progres-
sion ofbladder cancer, since they are found infrequently in super-
ficial tumours, but are detected at a high rate in late stage high
grade tumours. Patients with late stage (T2-T4) tumours with
detectable p53 mutations have a trend towards worse prognosis,
with our own studies showing a median survival ratio of3.54-4.46
(95% confidence interval) for normal compared with mutant p53
cases. For superficial tumours, a link between p53 mutations and a
higher risk of progression has been reported, but the results are
equivocal and larger studies are required. In ovarian cancer p53
mutation is more frequent in late stage poorly differentiated
tumours and complete response to pharmacologically defined
single agent platinum-based chemotherapy is strongly associated
with the absence ofdetectable p53 mutations.
In bladder and ovarian cancer mutational inactivation ofp53 is
frequently associated with abnormal p53 accumulation. However,
in a significant proportion of cases abnormal accumulation of
wild-type p53 protein occurs and this raises questions about the
functional integrity of p53 pathways in these tumours. In tumours
of the peripheral and central nervous system p53 staining in the
absence of mutations predominates and in neuroblastoma cyto-
plasmic sequestration of p53 has been reported. As understanding
of the mediators and modulators of p53 function has developed,
increasing attention is being devoted to assessment of the func-
tional integrity ofp53 related pathways rather than the mutational
status of p53 alone. New information on the role of WAFI and
mdm2 expression in bladder and ovarian cancer will be discussed.
Genetic alterations in in situ carcinoma and
putative precancerous lesions of the breast
SR Lakhani', N Collins2, MR Stratton2 andJP SloaneP
'Dept of Histopathology, UCLMS London WC1E 6JJ, 2Section of Molecular
Carcinogenesis, ICR, Surrey SM2 5PT and 3Dept of Histopathology, Royal
Liverpool University Hospital, Liverpool L69 3BX
Ductal carcinoma in situ (DCIS) and borderline lesions are being
encountered with increasing frequency since the introduction of
mammographic screening. Low Nuclear Grade variants of DCIS
are difficult to distinguish from LobularCarcinoma in situ (LCIS),
Atypical Ductal Hyperplasia (ADH) and florid Hyperplasia of
Usual Type (HUT). Unlike DCIS, LCIS is more often multifocal
and bilateral and invasive carcinoma subsequent to LCIS is often
ofthe ductal phenotype. Hence, there is doubt as to whether LCIS
is hyperplastic orneoplastic and whether it is a precursor lesion or
simply a marker of risk. Although considered benign, ADH is
associated with a significant risk of developing invasive carci-
noma. These considerations raise interesting questions about the
biological nature and interrelationships ofthese lesions.
Using a microdissection technique, polymorphic microsatellite
markers and thepolymerasechainreaction (PCR), loss ofheterozy-
gosity (LOH), at loci known to be present in high frequency in
invasive breast carcinoma (IC), was investigated in in situ carci-
noma and other proliferative lesions of the breast. 132 cases of
DCIS, 43 cases of LCIS, 14 cases of ADH and 51 cases of HUT
were examined for LOH on chromosomes 16q, 17p, 17q and 13q.
DCIS andLCIS showed a similarfrequency ofLOH to IC at the
loci studied (range 25-55%) apart from a locus on 17p (in the
vicinity ofTP53) where the frequency ofLOH in LCIS was much
lower (8% in LCIS vs 39% in DCIS). ADH exhibited a similar
frequency ofLOH to DCIS and IC. HUT, however, exhibited LOH
in only a small proportion ofcases (range 0-13%). There were no
morphological or cytological features in ADH or HUT that
predicted LOH.
The findings indicate that like DCIS, LCIS is a neoplastic prolif-
eration and likely to be a direct precursor of invasive carcinoma.
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The difference in LOH at 17p in LCIS suggests that the morpho-
logical and clinical differences between LCIS and DCIS are also
reflected at the genetic level. The similar incidence at other loci,
however, suggests that they may share a common pathway of
evolution. The evidence shows thatADH is aneoplastic ratherthan
a hyperplastic proliferation as its name implies and perhaps best
considered within the spectrum ofductal in situ neoplasia. At least
a proportion of HUT are also clonal and hence represent benign
neoplastic proliferations (adenomas) of the breast epithelium.
Hence these lesions are likely to represent non-obligate precursors
ofinvasive carcinoma.
Investigation of the progression of breast
cancer from ductal carcinoma in situ (DCIS)
to invasive carcinoma by comparative
genomic hybridisation (CGH)
EMoore', H Magee1, MMurphy1, J Coyne, PA Dervan1
'Department of Pathology, Biotechnology Centre, University College Dublin
and 2Withington Hospital, Manchester
Progression ofa tumour is presumed to involve a series ofgenetic
aberrations which conferincreasing growth factorindependence to
somatic cells. A novel technique, comparative genomic hybridisa-
tion (CGH)', is employed in which the relative intensities of
tumour DNA (detected with green fluorescence) and normal refer-
ence DNA (detected with red fluorescence) after hybridisation to
normal metaphase chromosomes is used to reveal and map
changes in DNA-sequence copy number. This approach has been
applied to the investigation of DNA copy number changes
involved in the progression of breast cancer from the earliest
recognisable stage, DCIS to invasive carcinoma. In this initial
study CGH was applied to 10 primary carcinomas, 6 high, 4 inter-
mediate and 2 low grade tumours and to 7 high, 1 intermediate and
1 low grade DCIS tumours. All carcinomas showed evidence of
increased or decreased DNA-sequence copy number changes. In
the invasive carcinomas the highest frequency of amplifications
occured at 8q22-24, 1q21-31, 17ql1-23.1 and 20q12-13 and
19q13.1, 11q24 and lp36 showing the highest frequency of dele-
tions. The DCIS cases revealed highest frequency of amplifica-
tions at lq22-42, 17q, 6qll.2-26 and 13q13-32 and deletions at
16p and 17. As fresh tissue for DCIS is rarely available it was
necessary to use formalin-fixed paraffin-embedded tissue forCGH
analysis. To investigate a possible shift in profile due to normal
and stromal cell contamination, DNA was extracted from
microdissected tumour cells and used for CGH analysis following
universal amplification by degenerate-oligonucleotide primed
PCR (DOP-PCR). We concluded that DNA from a tumour cell
population of > 50% is necessary for accurate CGH analysis.
These finding may provide the foundation for a future study of
specific and possibly novel genes associated with the different
grades ofbreast cancer.
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Expression of a BRCA1 allele containing a
12 bp insertion in intron 20
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In 1990, a breast/ovarian cancer susceptibility locus was mapped
to chromosome 17q21 and the gene, BRCA1 cloned in 1994. The
gene is 100 kb of genomic DNA and codes for a transcript of
7.5 kb. It is composed of 24 exons with exon 11 accounting for
more than 60% ofthe gene. Mutation analysis shows a wide spec-
trum of mutations occurring throughout the gene with little
evidence of mutational 'hotspots' and the majority of changes
resulting in frameshift or nonsense mutations. One variant which
has been described as a possible splice mutation is a 12 nucleotide
duplication, 48 bp downstream ofthe 3' end ofexon 20.
We have screened for BRCA1 mutations by SSCP and PTT in
germline DNA from members of nine families with a history of
early onsetbreast andovarian cancerandalso tumourDNAfrom 17
sporadic ovarian cancer patients. Four of the 17 cases have previ-
ously been shown to have partial deletions from chromosome 17 in
the region ofBRCA1 by loss ofheterozygosity. The remainder had
early onset disease, i.e. presentation before the age of45.
An SSCP band shift with exon 20primers was observed in the 3
affected members from one family and in tumour DNA from one
sporadic cancer patient which was subsequently demonstrated in
germline DNA as well. We did not detect this sequence alteration
in 134 control samples which included several patients with late
onset sporadic ovarian cancer as well as non-cancer controls.
We subcloned both the normal and variant alleles in these
patients into a pGEMt vector and observed the 12 bp duplication
48 bp into the intron as previously described. Archival breast
tumour DNA was available from one of the familial cases and
LOH studies with microsatellite polymorphisms demonstrated
widespread LOH from 17q. DNA from the sporadic ovarian
tumour did not show LOH in the region of BRCA1 but loss was
confined to distal 17q.
To determine if this insertion caused a splice site mutation, we
designed primers within exons 20 and 21 which amplified a 110 bp
fragment by RTPCR in both control RNA and RNA from the
archival tumour samples. Therefore it appears thatthis 12 bp dupli-
cation is a rare sequence variant, segregating with the disease.
Expression of connexin 43 and connexin 26
in human breast tumours
SJamieson', JJ Going2, R D'Arcy1 and WD George1
'Dept. of Surgery, Western Infirmary, Glasgow Gll 6NT, 2Dept. of Pathology,
Royal Infirmary, Glasgow G4 OSF
It has been proposed that gapjunctional intercellular communica-
tion (GJIC) plays a role in tumour suppression'. In support ofthis
idea, Lee et al2 found that the gapjunction gene products connexin
43 (Cx43) and connexin 26 (Cx26) were present in normal human
mammary epithelial cells but were lost in human breast tumour
cell lines.
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We have investigated expression of Cx43 and Cx26 in normal
human breast, 11 benign tumours and 27 invasive carcinomas of
the breast. Tissues were snap-frozen in liquid nitrogen and 5 gm
cryostat sections were acetone-fixed andprocessed forimmunocy-
tochemistry, using a biotin-streptavidin technique. Mouse mono-
clonal antibodies (Zymed) were raised against synthetic peptides
corresponding to Cx43 and Cx26 sequences.
We confirm previous reports of intercellular punctate Cx43
expression in the myoepithelium of normal human breast3'4. We
did not detect Cx26 in normal human breast, although we did
obtain clear punctate staining in the sweat duct and hair follicle
(outerroot sheath) ofcontrol skin sections. Others have previously
failed to detect Cx26 in human breast in vivo35 and whilst
Monaghan et al found Cx26 immunolabelling of ductal epithelial
cells, they could find no ultrastructural evidence for GJs in
these cells4.
Cx43 expression in fibroadenomas and a benign phyllodes
tumour resembled normal breast: only myoepithelial cells
expressed Cx43 and there was no expression ofCx26. Some inva-
sive carcinomas showed heterogeneous staining for Cx26 in the
carcinoma cells, but this was always cytoplasmic. Over halfofthe
invasive carcinomas showed heterogeneous staining for Cx43 in
the carcinoma cells and occasionally this was punctate and inter-
cellular. In addition, all carcinomas expressed punctate Cx43 on
the plasma membrane of elongated cells within the stroma, most
probably myofibroblasts.
Expression of Cx43 by myoepithelial cells and myofibroblasts
is consistent with expression of this connexin in other contractile
cells (cardiac muscle and myometrium). The aberrant expression
ofCx43 and Cx26 in invasive carcinomas is not inconsistent with
a role for GJIC in tumour suppression, but the heterogeneous and
predominantly cytoplasmic nature of this expression may simply
reflect the genetic and phenotypic instability ofthese tumours.
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Apoptosis is induced but Bcl-2 is unaffected
by tamoxifen and ICI 182780 in primary
breast cancer
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Hormonal breast cancer therapies have traditionally been consid-
ered cytostatic but pre-clinical data indicate that anti-oestrogens
can induce apoptosis, possibly by reversing oestrogen-induced
upregulation ofBcl-2.
We have measured apoptosis, proliferation, and Bcl-2 expres-
sion in primary breast cancer (PBC) patients before and after
presurgical treatment (Rx) with 20 mg/day Tamoxifen (TAM;
study 1) or 6 or 18 mg/day of the pure anti-oestrogen ICI 182780
(ICI; study 2). In each study there was a randomised no-Rx (NT)
control group. In study 1 median time to surgery was 21 days
(range 6-65 days). In study 2 presurgical Rx was for 7 days in all
patients. In study 1, apoptosis and proliferation were incorporated
as a growth index (GI) for each patient.
Proliferation was reduced in both Rx groups but not in the NT
groups (previously published). TAM significantly increased apop-
totic index (AI) in ER+ve (P < 0.05) but not in ER-ve tumours. GI
inER+ve TAM-treated patients was significantly lowerthan in NT
patients (P = 0.01) but there was no difference between the two
groups in ER-ve patients. There was a significant increase in AI
following Rx with ICI (median pre-Rx 0.34%, post-Rx 0.97%, P =
0.003). Insufficient pairs of samples were available to determine
whether this change was confined to ER+ve tumours, but Al was
significantly higher in excision biopsies from ICI-treated than
from NTpatients forER+ve (P = 0.005) but not ER-ve tumours (P
= 0.16). Bcl-2 was strongly associated with ER status before and
after TAM (P = 0.001 and 0.005, respectively). There was a trend
for Bcl-2 to be reduced in TAM-treated patients (P = 0.06), but
this trend was not confirmed in ER+ve patients. Bcl-2 expression
in excision biopsies was not significantly different between ICI-
treated and NT patients overall or according to ER status. There
was no significant correlation between Al and Bcl-2 in either pre-
or post-treatment TAM or ICI study groups.
This study provides the first evidence in patients that apoptosis
is induced in ER+ve primary breast cancer by both non-steroidal
and steroidal anti-oestrogens. This does not appear to be due to
changes in Bcl-2 expression.
An unusual p53 germline mutation in the
oligermerisation domain in a Li-Fraumeni-
like family
MELomax', DMBarnes2, R Gilchrist', SMPicksley3,
JM Varley4, RSCamplejohn1
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Investigations performed by Barnes et al (Lancet 340, 259, 1992)
demonstrated that patient 904005 had elevated levels of p53
protein in both the malignant and non-malignant cells of a breast
tumour. This unusual staining pattern was also seen in
keratinocytes, fibroblasts and endothelial cells at a site distant
from the tumour. The p53 protein could not be precipitated by the
PAb240 antibody, which is specific for p53 protein in the mutant
conformation, suggesting the p53 protein was wild-type in this
patient. Quantitative ELISA tests and Western blotting confirmed
that normal tissues from patient 904005 express higher levels of
p53 protein when compared to cells from normal individuals.
Despite extensive investigation, with the emphasis on the core
DNA binding domain, no germline mutation was found in the p53
gene (Barnes et al, 1992). In the present study, two recently
described functional assays for p53, an apoptotic assay and the
yeast based FASAY, have been employed to study the functional
activity of p53 in this patient. The results of the apoptotic assay
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suggest a p53-related defect and the results of the FASAY point
strongly to this defect being an actual p53 gene mutation. The
sequencing of the whole cDNA rescued from the yeast colonies
(codons 67 to 347) revealed a CGC to TGC mutation at codon
337, producing an Arg to Cys substitution. Sequencing of exon
10 of genomic DNA confirmed there was an Arg to Cys substitu-
tion at codon 337. This is an unusual mutation as it is in the
oligomerisation domain of the p53 gene, not the core DNA
binding domain which is the usual site of p53 mutations. The site
of the mutation in the p53 gene of this patient explains why the
p53 protein could not be precipitated by the PAb240 antibody. In
summary, it is possible for functional assays, such as the apoptotic
assay and FASAY, to detect a wide spectrum ofp53-related defects
with minimum time and effort, properties which are important if
large numbers ofLFS/LFL family members are to be screened for
p53 mutations.
Mspl polymorphism of the CYP4501Al is not
associated with increased risk of NSCLC in
NW England
HL Ross', TLiloglou1, A Swift', JR Gosneyk, RJDonnelly3
andJKField'
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In 1991 32 000 deaths in the UK were due to lung cancer. Most of
these cases were smoking related. However, only arelatively small
proportion of smokers develop lung cancer. It has been proposed
that individual differences in xenobiotic metabolism could place a
subset ofthe population at greater risk ofdeveloping lung cancer.
Genetic polymorphisms, particularly those in the cytochrome
P450 superfamily, have been studied in a number of populations
to see if they are over-represented in lung cancer patients.
CYP4501A1 is expressed only in the lungs of smokers and has
been shown to exhibit two polymorphisms. The first is the substi-
tution of valine for isoleucine due to a change in exon 7 and the
second is Mspl cleavage.
We studied the prevalence of the Mspl polymorphism in
patients with non-small cell lung cancer (NSCLC) to determine if
this was seen more frequently than would be expected in a control
population and could therefore be used as a marker for high risk
populations.
Restriction fragment length polymorphism (RFLP) was used to
examine the 3' flanking region of CYP4501A1 from 58 NSCLC
and 28 controls. Of 58 samples 13 were found to contain the
Mspl polymorphism, a frequency of 22.4%. This is not signifi-
cantly different from the frequency in the control population at
21.4% (6/28). This would suggest that the Mspl polymorphism in
the CYP4501Al gene is not associated with an increased risk of
developing lung cancer. This finding is in contrast to a previous
study on aJapanese population. It is possible that a combination of
polymorphisms, not only in the P450 superfamily but in other
enzymes involved in xenobiotic metabolism, may give a more
accurate guide to elevated lung cancer risk.
This research was supported by the Roy Castle Cause For Hope
Foundation.
PCR/ligase chain reaction (PCR/LCR) and
amplification refractory mutation system
(ARMS) techniques to assess K-ras
mutations for early lung cancer detection
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Mutations of the ras family of oncogenes are the most frequently
observed genetic lesions in a number of human malignancies.
About 80 to 90% of activating mutations of the K-ras gene occur
at codon 12 or 13 in human non-small cell lung cancer. Methods
are needed to screen rapidly for multiple mutations at K-ras codon
12 in premalignant clinical specimens such as bronchial washings.
Two techniques have been developed for K-ras mutation
detection: a polymerase chain reaction/ligase chain reaction
(PCR/LCR) technique and ARMS. The PCR/LCR technique
allows multiplex determination ofK-ras mutations in the firstbase
of codon 12. ARMS primers have been developed for determina-
tion of both first and second base K-ras codon 12 mutations.
PCR/LCR has been applied to human bronchial lavage (BL) spec-
imens and 84% ofthe BL specimens examined contain at least one
mutation in K-ras codon 12. By comparison, 9% of lung tumours
tested by ARMS displayed a mutation. The PCRILCR and ARMS
techniques have similar sensitivities. The high percentage of spec-
imens with K-ras mutations detected by PCR/LCR may indicate
the widespread presence of K-ras mutations on the bronchial
epithelium as sampled by BL.
Portions of this work are funded by a generous grant from the
G. Harold and Leila Y. Mathers Charitable Trust. Supported in part
by SPORE number CA58187-01 in the Lung Cancer Tissue
Laboratory at the University of Colorado Cancer Center and
SPORE number CA58184-01 at Johns Hopkins University.
The gastrin gene is activated early in the
progression of colonic polyps and Berrett's
oesophagus
AM Smith1, P Clarke1, N Grfinfi2, A Varro3, JD Hardcastle1
and SA Watson1
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Introduction: The gastrin gene has been shown to be activated in
colorectal and oesophageal adenocarcinoma. Both precursor and
mature gastrin peptides have been identified in tumourcells. These
peptides have been shown to have a proliferative effect and it has
been postulated that they act via autocrine/paracrine pathways.
The aim ofthis study was to determine the point in the progres-
sion of colonic polyps and Barrett's oesophagus the gastrin gene
becomes activated.
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Methods: Samples were taken from patients with colorectal
polyps (n = 55). Polyps ranged from tubular adenomas < 1 cm to
polyp cancers (n = 5, per group). Biopsies were taken from
patients with Barrett's oesophagus (n = 30, including all forms of
metaplasia and types ofdysplasia). Samples were also taken from
normal colonic (n = 5) and oesophageal mucosa (n = 5). Paraffin
embedded specimens were stained with polyclonal antisera against
progastrin glycine-extended gastrin, amidated gastrin and the
gastrin/CCKB receptor. Binding ofthe primary was detected using
two techniques, the avidin-biotin-peroxidase and alkaline phos-
phatase red methods. Samples were assessed blind by two inde-
pendent observers for site and degree ofstaining. Expression ofthe
gastrin and gastrin/CCKB receptor gene was confirmed by use of
the reverse transcriptase polymerase chain reaction.
Results: Immunocytochemistry demonstrated that progastrin,
glycine-extended gastrin, amidated gastrin and the gastrin/CCKB
receptor are expressed at high levels in the cytoplasm ofepithelial
cells in tubular adenomas < 1 cm and at a similar level in all forms
ofBarrett's metaplasia with no dysplasia. Gene products continue
to be over-expressed through all stages ofprogression in the colon
and oesophagus. Gastrin was not expressed in normal oesophageal
mucosa. In normal colonic mucosa expression was confined to the
neuroendocrine cells.
Conclusions: The gastrin gene is expressed at an early point in the
progression ofboth colonic polyps and Barrett's oesophagus. It may
have a proliferative effect as all components for an autocrine growth
pathway arepresent. Expressionofthegastrin geneearly inthedevel-
opment of adenocarcinomas at two sites in the gastrointestinal tract
may represent the reactivation ofadormant fetal growth factor.
Determination of genetic events in oral
cancer and precancer provides insight into
the molecular pathogenesis of early disease
and prognostic information
M Partridge1, G Emilion, S Pateromichelakis, RA'Hern2,
G Lee, EPhillips, MFalworth, JDLangdon
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Some oral cancers are preceded by potentially malignant lesions
which show varying degrees ofdysplasia. The clinical appearance
ofthese lesions does notpredictrisk oftransformation and markers
are needed to identify high risk lesions. Once cancer develops,
treatment depends on the extent of tumour spread and histological
features. However, the 5-year survival rate for oral cancer is
< 50%, suggesting that our current staging techniques and treat-
ment protocols may not give our patients the best chance ofcure.
We have used microsatellite assay with 51 markers to compare
dysplastic lesions which progressed to cancer and a group of
lesions which have not progressed, and screened primary SCC for
allelic imbalance at loci likely to harbour tumour suppressors for
this disease. The aim of the study was to help build databases of
relevant events, to see whether profiling the spectrum of genetic
abnormalities, in conjunction with studies determining gene
expression at the protein level, can provide insight into the molec-
ular pathogenesis of this disease as well as useful diagnostic and
prognostic information.
The analysis reveals that some matched dysplastic and malig-
nant lesions show genetic abnormalities in the dysplasia which are
not present in the corresponding tumour. This suggests that these
lesions arise from different clones and supports the concept of
field change within the oral cavity. However, other matched
lesions show similar genetic changes, suggesting that migration of
altered epithelial cells also occurs. Allelic imbalance at chromo-
somal regions at 3p2l, 3p13-12, 9p21, p53 and DCC was the most
frequent early event in the malignant process. Deletion mapping
has provided valuable insight into the chromosomal areas impli-
cated in this disease. The number of loci showing abnormalities
was increased in potentially malignant lesions which progressed,
and with advancing tumour stage.
A statistically significant relationship was observed between the
percentage of loci showing allelic imbalance (Al) and overall
survival. Patients were divided into three approximately equally-
sized groups on the basis of their percentage of Al. The relative
death rates in the low, intermediate andhigh imbalance groups were
1.0, 2.47, and 6.10 respectively (P < 0.001; the group with low Al
was used as the reference group). Multivariate analysis using Cox's
regression indicated thatthis relationship was independent ofstage.
This suggests that alteration of multiple growth regulatory path-
ways in a given tumour may help identify aggressive lesions.
Identification of a small number of key commonly occurring dele-
tions and mutations within each primary cancer will also enable us
to refine our existing staging techniques by providing the basis for
molecular methods to screen for disseminated disease.
Amplification and increased dosage of the
telomerase RNA gene in human cancer
Al Soderl, SFHoare', JJ Going3, S Muir', EKParkinson2,
WN KeithI
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Aim: Telomerase activity has been linked to cellular immortality
and tumour progression and has been discussed as a target for
chemotherapy. The aim was therefore to investigate genetic alter-
ations involving components of the telomerase enzyme complex
that could lead to increased telomerase activity.
Methods: A genomic clone containing the human telomerase
RNA gene was identified by screening the Du Pont Merck
Pharmaceutical Company human foreskin fibroblast P1 phage
library. Screening was carried out by Genome Systems Inc., St.
Louis, Missouri, using PCR primers directed to the hTR genomic
sequence. A clone was confirmed as containing hTR sequences by
the sequencing of PCR products generated using clone as a
template. This clone was mapped using fluorescence in situ
hybridisation (FISH). Interphase cytogenetic analysis was carried
out on frozen sections from73 biopsies from cervix, lung and head
and neck cancers using the cloned hTR sequences to quantitate
hTR gene copy number.
Results: We have accurately mapped the human telomerase RNA
gene to chromosome 3q26.3, a region frequently subject to copy
number gains in human tumours. The hTR gene was amplified in 4
tumours, (2/33 cervix, 1/31 SCC-HN, 1/9 lung tumours), and the
pattern of hybridisation indicated that the amplified sequences
were present either as integrated blocks or extrachromosomally. In
addition, increased copy numbers of the hTR locus was also
observed with up to ten copies per nucleus, and hybridisations with
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a chromosome 3 centromeric probe indicated that polysomy and
isochromosome 3q formation may contribute to this.
Conclusions: Our results are the first report of a genetic alteration
involving a known component of telomerase in human cancer and
support the notion that telomerase may be reactivated in some
human tumourtypes. Indeed, it is also the first report ofthe amplifi-
cation of a specific locus within the chromosome 3q region
frequently subject to copy number gains in human tumours.
The molecular pathogenesis of
polycytheamia vera
FA Asimakopoulos1, MA Aldred', JGR Gilbert', AJ Bench1,
PHHollings2 andAR Green'
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Acquired deletions of chromosome 20q are recurrent abnormali-
ties associated with myeloproliferative disorders, especially poly-
cythaemia vera (PV). The association ofthese deletions with 'stem
cell' disorders suggests that they may mark the site ofone or more
genes, loss or inactivation of which perturbs the regulation of
normal haematopoietic progenitors. We have previously used
quantitative Southern blotting and microsatellite PCR to charac-
terise 20q deletions at the molecular level (Asimakopoulos et al,
Blood, 84: 3086, 1994). These studies demonstrated telomeric and
centromeric breakpoint heterogeneity and defined a common
deleted region in PV of 16-21 cM. Several candidate genes such as
the tyrosine kinases SRC and HCK and the transcription factor
RBLI were found to map outside this region. However, this critical
region did contain known genes with a role in growth regulation.
Molecularanalysis ofblast DNA from apatient with PV/AMLhas
subsequently reduced the common deleted region to exclude the
genes for the tyrosine phosphatase PTPNI and transcription factor
CEBPbeta. A YACcontigcovering thisregion of 12-18 cM has been
constructed to provide a physical map prior to isolation and muta-
tional analysis offurthercandidate genes. Inaddition, twoapproaches
have been used to reduce the size ofthe common deleted region:
Firstly, microsatellite PCR analysis of granulocyte DNA from
48 patients with polycytheamia vera and no known 20q abnormal-
ities demonstrated that the main mechanism for loss of heterozy-
gosity ofchromosome 20q is interstitial deletion.
Secondly, an increasingly large panel of samples from patients
with 20q deletions has been analysed. Interestingly, none of the
deletion breakpoints fell within the common deleted region. Taken
together, these observations raise the possibility that simultaneous
deletion of several genes on chromosome 20q may be required to
produce a phenotypic effect.
Will molecular techniques supplant
immunocytochemistry in the detection of
occult melanoma cells in regional lymph
nodes?
AJ Cochran12, J Guo1, RR Huang1, D-R Wen'
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Immunohistochemistry (IHC) with antibodies to S-100 protein and
HMB-45 detects occultmelanomacells in lymph nodes tumour-free
on examination of HE stained sections. By this approach 14% of
patients with high risk melanoma had occult melanoma in at least
one node (CochranAJ, Surg Path 12:612, 1988) and 29% ofosten-
sibly melanoma-free nodes in lymphadenectomy specimens from
patients with node spread melanoma contained tumour (Cochran,
Int J Cancer 34:159, 1984). The sensitivity of this approach has
been widely confirmed. IHC evaluation of 'sentinel' lymph nodes
is the basis of the techniques oflymphatic mapping and selective
lymph node dissection (Morton, Arch Surg 127:392, 1992), for
high risk melanoma and other cancers. The approach requires
identification of the sentinel node, the first node on the direct
lymphatic drainage pathway from the primary and accurate deter-
mination as to whether that node contains tumour. Absent tumour,
no further treatment is undertaken. If tumour is present a full
lymphadenectomy is performed. When examined by solution
phase PCR, using a primer for m-tyrosinase, some nodes that do
not contain melanoma by IHC give a positive signal for m-tyrosi-
nase. Does this certainly indicate the presence of occult tumour?
There are several potential sources of m-tyrosinase in nodes that
could provide a confounding signal, including nerve-associated
Schwann cells and nevocytes in the node capsule (Carson, Surg
Path 20:834, 1996). The true source of signal can be determined
only by techniques, such as in situ RT-PCR, that combine cyto-
logic identification of the source of signal with amplification of
signal from single cells to readily detectable levels. We will
demonstrate the successful application of in situ RT-PCR to
melanoma cells in culture and in sections from formalin-fixed and
paraffin embedded blocks. Application ofthese in situ approaches
to the sentinel nodes will disclose whether all nodes that contain
m-tyrosinase on solution phase PCR actually contain occult
melanoma. (NCI CA2960)
Detection of neuroblastoma cells by RT-PCR
for tyrosine hydroxylase
SA Burchill, RA Harrison', FMBradbury, P Selby and
IJLewis3
'Children's Cancer Research Laboratory, 2Cancer Medicine Research Unit
and 3Paediatric Oncology, SJUH, Leeds LS9 7TF
Disseminating disease is important in the clinical outcome for
patients with neuroblastoma. We have examined detection of
neuroblastoma cells in peripheral blood (PB), bone marrow (BM)
and peripheral blood stem cell harvests (PBSCH) by RT-PCR for
tyrosine hydroxylase (TH).
Using this method it is possible to detect a single neuroblastoma
cell in 1 ml of whole blood or bone marrow. No TH mRNA was
detected in control PB (20), BM (6) or PBSCHs (4). TH mRNA
was detected by RT-PCR in all 16 neuroblastomas examined.
A strong correlation was found between detection ofTH mRNA
by RT-PCR and metastatic disease status detected by conventional
methods in 40 patients. In two patients, neuroblastoma cells
detected by RT-PCR for TH mRNA at diagnosis were detected
throughout and at the end of therapy. These patients appeared not
to respond to therapy and relapsed within 12 months ofdiagnosis.
Both these patients have subsequently died oftheir disease.
Analysis ofblood samples from 30patients identifiedcirculating
tumour cells in 26% clinically disease free patients. On follow-up
71% of patients with circulating tumour cells relapsed and died,
compared to 10% of those without. TH mRNA transcripts were
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detected in peripheral blood up to 12 months before urinary cate-
cholamine levels began to increase and clinical relapse occurred.
Comparative analysis ofblood samples before clinical relapse and
at the time of relapse demonstrated an increase in circulating TH
mRNA at relapse, suggesting an increase in the number of circu-
lating tumour cells.
In summary, RT-PCR for TH is a sensitive and specific method
for the detection of circulating disease in neuroblastoma. This
method may be used to monitor BM orPBSCHs forcontaminating
tumour cells, though the precise risk associated with tumour cell
contamination ofBM or PBSCHs used in engraftment is not clear.
Preliminary evidence demonstrates the level ofcontamination may
be substantial and will vary depending on the time of harvest.
Longterm clinical significance of neuroblastoma cell detection
is currently being evaluated through the UKCCSG study number
NB 9305.
Presented on behalf of the United Kingdom Children's Cancer
Study Group.
Characterisation of small round cell tumours
of childhood by tissue specific RT-PCR
SA Burchill, C Cullinane2, J Wheeldon', P Roberts3 and
IJ Lewis4
'Cancer Research Unit, 2Depts of Pathology, 3Cytogenetics and
4Paediatric Oncology, SJUH, Leeds LS9 7TF
Small round cell tumours in children are often difficult to distin-
guish from each other using conventional methodologies. The aim
of this study was to identify potential targets for RT-PCR charac-
terisation of small round cell tumours and compare this with stan-
dard histopathology and cytogenetics. Targets chosen for study
included tyrosine hydroxylase (TH) for neuroblastoma, MyoDl
for rhabdomyosarcomas, EWS-FLII fusion transcripts for
Ewing's and pPNETs, and the PAX3-FKHR fusion transcript for
alveolar rhabdomyosarcomas.
RNA was extracted from small round cell tumours including
neuroblastoma, pPNET, Ewing's and rhabdomyosarcoma. This
RNA was reverse transcribed to produce cDNA and using poly-
merase chain reaction amplified forexpression ofTH, EWS-FLI1,
PAX3-FKHR and MyoDI mRNA. Extraction ofRNA, subsequent
reverse transcriptase polymerase chain reactions and analysis of
products was performed in designated lamina flowhoods and
rooms. The identity of the amplified products was confirmed by
liquid hybridisation and sequence analysis.
Good quality RNA was extracted from all tumour samples; all
were positive for the house keeping gene ,2-microglobulin. 11/11
neuroblastomas were positive for TH, 6/6 rhabdomyosarcomas
were positive for MyoDl and 6/6 Ewing's/pPNETs positive for
EWS-Flil mRNA, demonstrating a strong correlation between RT-
PCR and conventional analysis. However, 30% of these tumours
were bi or triphenotypic. 2 neuroblastomas and 1 rhabdomyosar-
coma were positive for EWS-FLII mRNA, and 1 Ewing's was
also positive for TH. Two rhabdomyosarcomas and 1 pPNET
expressed mRNA for EWS-FLII, MyoDl and TH. None of the
samples expressed mRNA for the PAX3-FKHR translocation.
In summary, analysis by RT-PCR for tissue specific gene
expression appears to aid differential diagnosis ofsmall round cell
tumours. Although these results demonstrate expression of the
chimeric EWS-FLII, TH or MyoDl transcripts in phenotypically
distinct tumours, a subset of the tumours examined demonstrate
characteristics of mixed phenotype. The presence of EWS-FLIl
mRNA in neuroblastomas and rhabdomyosarcomas suggests
EWS-FLI1 transcripts are not necessarily pathognomonic of
Ewing's and pPNETs. These results may have implications for
understanding small round cell tumourbiology.
Identification of a protein phosphatase 2A
regulatory subunit differentially expressed in
malignant cells
GFFrancia, R Poulsom1, SD Mitchell, JFMarshall
andIR Hart
Richard Dimbleby Dept./ICRF Unit, Rayne Institute, St Thomas' Hospital,
London SE1 7EH. 'ICRF Histopathology Unit, Lincoln's Inn Fields, London
WC2A 3PX
We previously reported the identification by rtPCR of four
transcripts differentially expressed between murine B16F10
(metastatic melanoma) and Melan-a (immortalised melanocyte)
syngeneic cell lines (Francia et al, CancerRes 56: 3855 1996). We
now show that one such transcript is the mouse homologue ofthe
human B56yregulatory subunit ofprotein phosphatase 2A(PP2A).
By Northern blotting analysis this transcript is detected only in the
metastatic B16F1O cells but not in Melan-a nor in simply tumouri-
genic (Melan-ab/LTRras) or weakly metastatic variants (B16F1).
The full coding region of the murine homologue has been cloned
and found to be 90% identical to its human homologue. Using
homologous probes we have examined expression of the human
gene in neoplastic tissue by two procedures, Northern blotting and
in situ hybridisation.
Northern blotting analysis of the human B56y regulatory
subunit showed overexpression in human melanoma cell lines
established from metastatic disease (A375P, A375M, HMB2) rela-
tive to normal epidermal melanocytes. By in situ hybridisation a
weak tissue-wide distribution was observed with evidence ofover-
expression in carcinomas ofthe ovary and colon. These data show
that a murine gene, detected as being differentially expressed in a
model of tumour progression, has a human counterpart which
shows comparable variation of activity. Since PP2A activity is
regulated by B56yit seems possible that this association reflects a
difference in phosphatase activity in malignant tissue.
Prevalence and prognostic significance of
expression of p53 and bcl-2 gene proteins in
Ewing's sarcoma of bone
A Abudu, DCMangham, GM Reynolds, PB Pynsent,
RM Tillman, SR Carterand RJ Grimer
Royal Orthopaedic Hospital Oncology Service, The Royal Orthopaedic
Hospital, Birmingham B31 2AP, UK
Immunohistochemistry was used to study abnormalities of p53
and bcl-2 genes in biopsy tissues of 52 patients with Ewing's
sarcoma of bone to determine their significance in diagnosis and
prognosis of the disease. Mean age was 17 years. Minimum
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follow-up was 30 months. Tumours were located in the extremities
and central bones in 35 and 17 patients respectively. Seven patients
had metastases at diagnosis.
p53 protein was expressed in 7 patients (14%) and bcl-2 in 12
patients (23%). There was no relationship between expression of
these proteins and tumour stage, site and necrosis following
chemotherapy (P > 0.5). Five year relapse-free survival and
overall survival in patients without metastases at diagnosis were
66% and 71% respectively in p53 protein negative patients
compared to 20% relapse-free and overall survival in those with
p53 protein expression (P = 0.01). The poorer prognosis in p53
protein positive patients was independent ofsite, local treatment or
necrosis ofthe tumours (P = 0.02).
bc1-2 had no influence on survival. There was no statistical
relationship between expression ofbcl-2 and p53 proteins. Three
patients expressed both bcl-2 and p53 proteins but the disease
course in these patients was not different from the course of
disease in patients with expression ofjust one protein.
p53 protein is an independent poor prognostic factor in Ewing's
sarcoma of bone. bcl-2 protein expression has no prognostic
value or relationship to expression ofp53 proteins in patients with
Ewing's sarcoma.
Molecular cloning and expression of the
human hyaluronan receptor rhamm in breast
cancer cells
VAssmann, JFMarshalland IR Hart
R Dimbleby Department of Cancer Research/ICRF Laboratory,
The Rayne Institute, St Thomas' Hospital, London SE1 7EH
A characteristic ofinvasive, as compared with in situ breast carci-
noma cells, is the acquisition of motility enabling them to pene-
trate the epithelial basement membrane and enter the underlying
ECM. We have investigated the potential role of the hyaluronan
(HA) receptor RHAMM (receptor for hyaluronan-mediated
motility) in breast cancer. RHAMM has been shown to mediate the
HA-dependent migration ofvarious cell types including ras-trans-
formed fibroblasts, B- and T-lymphocytes. We have isolated a
cDNA clone which codes forthe human HA-receptor RHAMMby
screening of a lambda gtl1 expression library, derived from the
endometrium carcinoma cell line Ishikawa, using PCR-based
approaches. The predicted human RHAMM sequence possesses
significant homology to the murine RHAMM sequence (84%
homology in the overlapping region). A single RHAMM gene
transcript is expressed in the eight breast cancer cell lines investi-
gated by RT-PCR analysis and Northern blot hybridisation. To
examine the expression of the RHAMM protein we have raised a
polyconal antibody against a bacterially expressed glutathione-S-
transferase (GST)-RHAMM fusion protein. The antiserum detects
an 85-90 kDa protein in Western blot analysis and is expressed by
all the breast cancer cell lines examined. Surprisingly, the anti-
RHAMM antibody does notlabel the cell surface, butthecytoplasm
and nucleus, of breast cancer cells in immunofluorescence studies.
In addition, RHAMM proteins were not accessible to surface
labelling by iodination or biotinylation. In contrast, the 85 kDa
RHAMM protein was immunoprecipitated from 35S-methionine-
labelled whole-cell extracts indicating an intracellular localisation
of the antigen. Preliminary data from immunohistochemical
staining ofprimary breast cancers showed an increased expression
of RHAMM in the cytoplasm and the nucleus of tumour cells
compared to normal breast epithelium. In addition, RHAMM gene
transcripts were barely detectable in normal breast epithelial cells
by Northern blot analysis. Takentogether, ourfindings indicate the
RHAMM is likely not to function as a cell motility receptor in
human breast cancer cells but instead its intracellular localisation
strongly suggests that RHAMM belongs to a novel family ofintra-
cellularhyaluronan-binding proteins.
Stimulation of pro-MMP-2 release in cultures
of human fibroblasts and ovarian carcinoma
cells
RS Boydand FR Balkwill
Biological Therapies Laboratory, ICRF, London WC2A 3PX, UK
Ovarian carcinoma contains elevated levels of MMP-2, much of
which is in an activated form. Co-culture of human fibroblasts,
dermal and breast tumour derived, and the ovarian carcinoma
cells, PEOI, PEO14 and SKOV-3, resulted in an increase (2-8-
fold) in supernatant pro-MMP-2 levels, as determined by quantita-
tive gelatin zymography. This interaction between fibroblasts and
carcinoma cells was found to involve both soluble factor(s) and
cell-cell contact. Cell contact was the most important component
of the interaction. Use of RT-PCR indicated that both fibroblasts
and carcinoma cells expressed mRNA for EMMPRIN, a recently
described membrane bound stimulator of pro-MMP-2 release.
PE014, SKOV-3 and fibroblast cells were found to express
mRNA for the pro-MMP-2 activator, MT-MMP 1, and MT-MMP
1 protein could be detected in the human dermal fibroblasts. Co-
culture ofcarcinoma and fibroblast cells, however, resulted in only
a minor activation of supernatant pro-MMP-2 (< 5%). In conclu-
sion, co-culture of ovarian carcinoma cells and fibroblasts results
in an enhanced release of pro-MMP-2 but no activation of this
enzyme.
FGF1, FGF2 and FGF8 co-expression in
human prostate cancer
HYLeung1, TDorkin', CMarsh2, MRobinson2 and
DENeal1
'Dept of Surgery, The Medical School, University of Newcastle NE2 4HH;
2Dept of Pathology, Freeman Hospital, Newcastle NE7 7DN
Introduction: Fibroblast Growth Factors (FGFs) are important
mitogens and may contribute towards to the pathobiology of
human prostate cancer. We have recently described over-expres-
sion of FGF8, or androgen-induced growth factor, in prostate
cancer(Oncogene 1996, 12, 1833). As different FGFs may interact
with individual high affinity FGFreceptors (FGFRs), we have now
extended our study to examine the expression ofFGF1 (aFGF) and
FGF2 (bFGF) on the same cohort ofcases.
Method: Thirty-one cases ofprostate cancer (5 well differentiated,
10 moderately differentiated and 16 poorly differentiated) and
5 cases of benign prostatic hyperplasia (BPH) were used.
Immunohistochemical analysis using specific antibodies against
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human FGFl and FGF2 were performed as described previously
(Cancer Res 1993, 53, 4741). Negative control was performed for
each case by omitting the primary antibody. Immunoreactivities
were assessed without clinico-pathological details and were
graded as negative, weak, moderate and strong.
Results: Over-expression of FGF1 and FGF2 were noted in the
malignant prostatic epithelium. FGF1 expression was observed in
80% (25/31) of prostate cancer. High grade tumours appeared to
express FGF1 at higher levels, but this assocition failed to reach
statistical significance. FGF2 immunoreactivity was observed in
55% of prostate cancer; with no relation to tumour grade.
Immunoreactivities for FGF1 and FGF2 were cytoplasmic and
homogeneous among tumour cells. At areas of prostatic intra-
ductal neoplasia and peri-neural invasion, high levels of FGF1
expression were observed. In the adjacent benign prostatic epithel-
ium, the epithelial cells stained negative for FGF1 and FGF2.
Staining for FGF1 and FGF2 within the stroma was only seen in
small proportion of the cases and the signals were at low intensi-
ties. BPH did not show any significant staining for FGF1 and
FGF2. FGF8 over-expression was previously found in 71%
(22/31) ofthe prostate cancer in this series.
Conclusions: FGF1, FGF2 and FGF8 co-expression exists in
human prostate cancer, with FGF1 being most commonly
expressed, followed by FGF8 and FGF2. Their over-expression
appeared to be restricted to the malignant prostatic epithelium.
Future work on the expression and interaction between multiples
of FGFs and their high affinity FGFRs will allow better under-
standing ofthe role ofFGFs in prostate cancer.
Transcription of the SCL gene in erythroid
and CD34 positive primitive myeloid cells is
controlled by a complex network of lineage-
restricted chromatin-dependent and
chromatin-independent regulatory elements
B Gdttgens1, FMcLaughlin1, E-O Bockamp1, AG Elefanty2
andARGreen1
1University of Cambridge, Dept. of Haematology, MRC Centre, Hills Road,
Cambridge CB2 2QH, 2The Walter and Eliza Hall Institute of Medical
Research, Melbourne, Victoria, 3050, Australia
The SCL gene (also known as TAL-1) encodes a basic helix-loop-
helix transcription factor that is essential for the development ofall
haematopoietic lineages. Rearrangements ofthe SCL gene are also
the commonest molecular pathology associated with T cell acute
lymphoblastic leukaemia. SCL is normally expressed in pluripotent
haematopoietic stem cells and its expression is maintained during
differentiation along erythroid, mast and megakaryocytic lineages,
but is extinguished following commitment to other cell types. The
mechanisms responsible for this pattern of expression are poorly
understood, but are likely to illuminate the molecular basis for stem
cell development and lineage commitment.
Here we describe the identification of7 lineage-restricted DNase
I hypersensitive sites in a 45 kb region spanning the murine SCL
locus. Committed erythroid cells and CD34 positive primitive
myeloid cells exhibited different patterns ofDNase I hypersensitive
sites. The function ofeach hypersensitive site has been studied using
both transient and stable reporter assays in erythroid, primitive
myeloid and T cells. Multiple cell-specific regulatory elements have
been identified. In particular a 3' element (+17HS/+18HS) func-
tioned as a potent erythroid enhancer, an intragenic element (+7HS)
functioned as a chromatin-dependent silencer in primitive myeloid
cells and another intragenic element (+3HS) functioned as a chro-
matin-dependent enhancer in both erythroid and primitive myeloid
cells. Our results represent the first description of several key
components of a complex network of regulatory elements control-
ling SCL expression during haematopoiesis.
Therapeutic potential of anti-EGFR
antibodies in antagonising the effects of the
EGF family of ligands
H Modjtahedi1, BD Cohen2 and C Dean'
'The Institute of Cancer Research, McElwain Labs, 15 Cotswold Road,
Belmont, Surrey, UK, 2Bristol-Myers Squibb Pharmaceutical Research
Institute, 3005 First Avenue, Seattle, USA
Overexpression of the epidermal growth factor receptor (EGFR)
accompanied by production ofone or more ofits ligands has been
reported in a wide range of human malignancies and this in turn
has been associated with a poorer survival in many of these
patients. Since the ligand-induced activation of such cells occurs
via receptors on the cell surface rather than intracellularly, such a
system may form a suitable target for monoclonal antibody
(mAb)-directed therapy. We have described previously the produc-
tion and characterization of a number ofmAbs which are directed
against five distinct epitopes on the external domain ofthe human
EGFR and have been investigating their potential for diagnostic
and therapeutic application in oncology. We have shown recently
that mAbs which block the binding of the EGF, TGFa, heparin
binding EGF-related growth factor (HB-EGF) and betacellulin
(BTC) to the EGFR also 1) block the ligand-induced tyrosine
phosphorylation ofthe EGF receptor, 2) inhibit the growth both in
culture and in vivo of tumours which overexpress the EGF
receptor, and 3) can be administered safely and localise efficiently
to metastatic lesions in patients with head and neck or lung cancer.
If these antibodies are to be therapeutically effective, they must
alsoblockthe activation oftheEGFR inducedby any memberofthe
EGF family of ligands. In the present study, we have investigated
whether, like other EGFR ligands, amphiregulin (AR) transmits its
biological effects following binding to the EGF receptor and
whether such effects could be antagonised in the presence of anti-
EGFR mAbs. We show that like the other EGFR ligands, AR could
inhibit the growth in culture of EGFR overexpressing tumour cell
lines, namely HN5, HSC-I and MDA-MB468 cells andinduce tyro-
sine phosphorylation of the 170 kDa EGF receptor on HN5 cells.
These effects were blocked in the presence of mAbs ICR62 or
ICR80. However, unlike the other ligands, AR was unable to A)
prevent the binding of 125I-EGF or the mAbs 125I-ICR62 and 125I-
ICR80 to EJ cells or B) enhance the binding of another anti-EGFR
mAb ICR9 to the EGF receptor on EJ cells. These results indicate
that, despite activating the EGF receptor, AR, unlike the other
ligands, does not bind to this receptor. On the basis of our data we
conclude that the AR-induced activation of the EGFR, which may
be mediated via hetero-dimerisation and transphosphorylation by
another receptor, can be blocked in the presence of anti-EGFR
mAbs. (Supported by the Medical Research Council, UK.)
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The role ofTGFP,1 in human colon cancer
JM Bowman', Z Taylor', MO Smith', JA Royds2, J Lawry'
Institute for Cancer Studies' and Department of Pathology2, University
Medical School, Beech Hill Road, Sheffield S10 2RX
TGF,1 is one member of a family of regulatory proteins having
variable effects depending upon the cell type, stage of differentia-
tion and ambient growth conditions. It is generally considered to
be growth inhibitory on cells ofepithelial origin, and acts via three
surface receptors (Type I, II and III) in regulating GI to S-phase
progression through the actions of the cyclin dependent kinase
inhibitors (CDKIs) p15, p21 and p27. In colon tumour progression
TGF3, switches to being growth stimulatory, and has been linked
with recurrence and metastases.
In vitro proliferation studies were undertaken using flow cyto-
metry to measure cell cycle and BrDu incorporation in three colon
cell lines. TGF3, was growth inhibitory for HT29 cells and moder-
ately so for HCT116 cells. In contrast, the SW742 line was bi-
responsive, being growth inhibited by TGFI, in the presence of
serum, and stimulated in the absence of serum. All cell lines
expressed high levels of Type II receptor (low levels of Type I);
both being required to generate a heterodimeric complex capable
of signal transduction. Expression of both receptors was always
down regulated by TGFfB1, which also modulated cell cycle related
proteins. In the growth inhibited HT29 cell line p27 (Kipi ) expres-
sion was significantly increased, which acts as an inhibitor of the
cyclin E/CDK2 complex normally required for entry into the cell
cycle; whilst p15 and p21 expression was reduced. In contrast,
under growth stimulatory conditions, the SW742 line had low
level p27, high levels ofp15 and p21.
In vivo studies of36 archival samples ofcolon adenocarcinoma
and 10 adenomatous polyps, using immunohistochemistry, were
carried out in parallel to determine the potential correlation
between TGFP,1 synthesis, the expression of receptors Type I and
II, CDKI and cyclins, and stage ofthe disease. In particular, it was
found that Dukes' B samples were Type II receptor positive and
Type I receptor negative, with the reverse situation in Dukes' C
and D samples. This effect may result in a loss of response to the
inhibitory effects of TGFP,. Type I receptor may prove to be a
prognostic marker ofdisease progression.
We believe this study represents the first link between TGFfiI,
p27 expression and the control of GI to S-phase progression via
the cyclin E complex, with reciprocal effects detected in the
expression of p5 and p21.
This research is funded by the Y.C.R.C.
Recombinant mycobacteria as cancer
vaccines
AMJackson', MA Chambers2, XZhu', J Haley3, P Patel',
REBanks1, MAO'Donnell4, KJames3 and PSelby'
'ICRF Cancer Medicine Research Unit, University of Leeds, 2Molecular
Genetics, Central Vetinary Labs., Weybridge, 3Dept. Surgery, University of
Edinburgh, 4Dept. Urology, Beth Israel Hospital, Boston, USA
Intravesical immunotherapy with live BCG vaccine yields
complete responses in 75% of patients with CIS of the bladder.
Favourable responses are associated with elevated levels of urinary
cytokines and observations have been made showing particularly
low levels of several interleukins in patients with persistent malig-
nancy. Although the mechanisms ofaction ofBCG therapy are not
fully understood, it is likely that the success ofBCG is attributable
to local infiltration of activated leukocytes and their specific and
non-specific cytotoxic activities. We are investigating the feasi-
bility ofengineering cytokine-secretion by mycobacteria for cancer
therapy and vaccination.
Recently E. coli-mycobacterial 'shuttle' vectors have been devel-
oped which use hsp7O promoters to drive expression of a recombi-
nant gene. Modified forms of these vectors include the BCG
alpha-antigen signal sequence (which facilitates secretion of
proteins) in fusion with the recombinant gene. An interesting feature
of this expression system is the incorporation of a second hsp6O
promotor driving expression ofA. victoria green-fluorescent-protein
(gfp). When excited by UV or laser radiationgfp emits visible green
light, making it particularly useful for localising and tracking
mycobacteria. Usingoverlap-extension RT-PCR wecloned anumber
ofcytokines fromhuman and murine mRNA into 2 vectors, pMOD-
8 and pMOD-12. Preliminary experiments were undertaken with M.
smegmatis due to its non-pathogenic nature and relatively rapid
growth in culture. The levels ofcytokine expression as measured by
specific ELISA were as follows; IL-7 (10 pg/ml), IL-8 (50 ng/ml),
IL-15 (300pg/ml), RANTES (20ng/ml), MCP-l (150ng/ml).
The unique difficulties of recombinant gene expression in
mycobacteria, our initial results on the biological activities of
mycobacterial-derived cytokines, and the future uses for this
system to express tumour antigens in conjunction with cytokines
will be discussed.
Characterisation of nitroreductase as a
'suicide gene' for cancer gene therapy:
hypoxia and cell cycle effects
SMBailey*, R Gilchrist, RS Camplejohn and IR Hart
Richard Dimbleby Dept. of Cancer Research, St Thomas' Hospital,
London SE1 7EH
E. coli nitroreductase is a 'suicide gene' proposed for use in cancer
gene therapy. We have shown previously that V79 Chinese hamster
lung cells transduced with the nitroreductase gene exhibit increased
sensitivity to the nitro compounds CB 1954 and nitrofurazone rela-
tive to control cell lines. We have now extended the study and char-
acterised this 'suicide gene' system in terms of the mechanism of
cytotoxicity and effect of hypoxia. MCF-7 human breast cancer
cells were transfected with plasmids containing either the nitrore-
ductase gene in the sense or antisense orientation, driven by the
CMV promoter, or control vectors. Stable clones were selected
with puromycin. Nitroreductase expressing clones were up to 525-
fold more sensitive to CB 1954 and 75-fold more sensitive to nitro-
furazone compared with the control cells. The existence of a large
differential was confirmed by clonogenic assay. Marked cell cycle
perturbations were induced in a V79 nitroreductase expressing
clone (F83-2) following treatment with cytotoxic (-99% cell kill)
concentrations of CB 1954 (0.01 mM), including slowing in
progression ofcells through the cycle followed by accumulation in
the G2/M phase. This drug concentration caused no effect in a
clone transfected with the antisense vector (F80-18) but cell cycle
perturbations were observed when an equitoxic dose of CB 1954
(10 mM) was used. Similar results were obtained for MCF-7 cells.
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Nitrofurazone also induced cell cycle perturbations in V79 cells
but, interestingly, this compound appeared to completely block
progression through the cell cycle, thus indicating a different mech-
anism of action to CB 1954. The effect ofhypoxia on CB 1954- or
nitrofurazone-induced cytotoxicity also was investigated. For the
V79 nitroreductase expressing clone, F83-2, there was no differ-
ence between the sensitivity of cells to either drug under hypoxic
versus aerobic conditions. In contrast, the V79 antisense clone
(F80-18) was 12-fold more sensitive to CB 1954 and 7-fold more
sensitive to nitrofurazone under hypoxic compared with aerobic
conditions. These data suggest that agents with a different mecha-
nism of action may be useful for nitroreductase gene therapy.
In addition to targeting nitroreductase-expressing cells, these
compounds could operate as dual function agents since they are
more cytotoxic to hypoxic tumour cells than to oxic counterparts.
In vivo quantification of thymidine salvage as
a pharmacodynamic endpoint of thymidylate
synthase inhibition
P Wells, RN Gunn, JC Matthews, A Hughes2, G Taylor2,
IRafi2, DRNewelP and PPrice1
'MRC Cyclotron Unit, Hammersmith Hospital, London W12 OHS, 2Cancer
Research Unit, Medical School, University of Newcastle upon Tyne,
Newcastle NE2 4HH
3,4-Dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quina-
zolone dihydrochloride (AG337) is a nonclassical thymidylate
synthase inhibitor (TS) developed to overcome potential resistance
mechanisms which limit activity ofclassical antifolates and is being
evaluated in aCancerResearch Campaign (CRC) Phase I study. It is
anticipated that thymidine salvage pathways will be activated in
tissues following treatment. Positron Emission Tomography (PET)
with [2-''C]thymidine has been used to demonstrate this effect
which may reflect the degree ofTS inhibition.
Five patients with metastatic colorectal cancer were studied.
[2-'"C]thymidine PET scans were performed on two separate occa-
sions, one before treatment and one on the second day of therapy,
one hour after oral administration of AG337 (250mg/M2). The
thymidine scans were acquired over 60 minutes following intra-
venous administration oftracer doses ofradiolabelled [2-'"C]thymi-
dine (maximum of 555 MBq). Three paired control studies were
performed at one week intervals with no intervening treatment to
assess reproducibility. In addition to the tomographic data, arterial
blood samples were acquired from which a plasma thymidine input
function was derived. Spectral analysis is a deconvolution method
used to calculate the tissue impulse response function (IRF) which
was used to characterise uptake (IRF at 60 minutes) and delivery
(initial IRF accounting for blood volume). The PET derived
measure is expressed as the fractional retention of tracer at 60
minutes (FRT) which equals uptake/delivery, as previous work has
suggested that correction for tracer delivery is necessary.
Data on five treated patients are described. For tumour there
was a significant increase in FRT and uptake post AG337 treat-
ment relative to control studies (paired test P = 0.04). A notable
(but not significant) increase was seen for spleen, whereas no
change was noted in liver regions sampled. These results are
consistent with enhancement of the thymidine salvage pathway
following TS inhibition, reflected by an increase in labelled thymi-
dine concentration in tumours relative to normal tissue.
This work is supported by CRC Grant No SP2 193/0102 and
Schering Plough.
In vivo demonstration of 11C-Temozolomide
uptake by human recurrent high grade
astrocytomas
CS Brock1, JC Matthews', G Brown1, ES Newlands2
and P Price'
MRC Cyclotron Unit, Hammersmith Hospital', and Dept. of Medical
Oncology, Charing Cross Hospital2, London
The oral prodrug temozolomide is an imidazotetrazine derivative
with cytotoxic activity in brain tumours.
Four patients with recurrent high grade gliomas receiving temo-
zolomide as part of the CRC Phase I & II trials were studied.
Tracer doses (50 mcg) of temozolomide radiolabelled with "C
(555 MBq) in the 3N-methyl position were injected intravenously
and repeat studies were performed during therapeutic treatment.
This was preceded by a 60 second infusion of H2150. Positron
emission tomography (PET) scans were performed on a 953B
Siemens NeuroPET scanner for 90 minutes ("C-Temozolomide
("C-Tem)) and 4-6 minutes (H2150). Blood radioactivity was
monitored for the scan duration using continuous arterial sampling.
Tumour and normal tissue regions of interest were defined and
applied to the dynamic PET images producing tissue and tumour
time activity curves (TACs) of the mean pixel radioactivity. Once
corrected for radiolabel decay, body surface area and injected dose
of tracer the areas under the curve (AUC) were calculated. Tissue
and tumour perfusion were calculated from the measured 150
concentration in arterial blood and the PET H2'50 time activity
curves by the numerical fitting of a Kety-Schmidt model.
There was no significant correlation detected between tumour
perfusion and tumour ("C-Tem) AUC (r2 = 0.2074). It may be that
changes in perfusion do not affect temozolomide uptake or a more
confounding variable, such as blood-brain barrierdisruption, have
a greater effect on drug uptake as measured with AUC. There was
no significant difference between tumour perfusion in the tracer-
only and temozolomide studies during treatment, suggesting that
there is no evidence that temozolomide alters perfusion. There was
significantly greater uptake of "C-Tem by tumour as compared
with normal contralateral brain (P = 7.7405e-6, paired t-test). For
AUCs corrected for perfusion there was a greater percentage
difference between tumour and contralateral brain (uncorrected
66 ± 16%; corrected 134 ± 33%).
PET allows in vivo demonstration of normal tissue and tumour
perfusion and drug pharmacokinetics.
Temozolomide was developed by the CRC and is now licensed
to Schering Plough. This work is supported by CRC grant no SP2
193/0102.
Universal immuno-PCR for ultrasensitive
detection of DNA repair components and
other antigens
Marian Case1, AlastairD Burt2, Margaret FBassendine1
and Glenn NMajor1
Departments of Medicine' and Pathology2, The Medical School, University of
Newcastle, Newcastle upon Tyne NE2 4HH
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Incidental human exposure to potentially carcinogenic alkylating
agents is likely to yield very low levels of tissue DNA damage
(adducts). Detection and quantitation of such low-level damage is
technically difficult. This is the case for the powerfully promuta-
genic DNA base lesion 06-methylguanine, which may be produced
in human DNA following exposure to methylating agents such as
the environmentally ubiquitous nitrosamines. We have assessed the
feasibility ofusing immuno-PCR, a potentially extremely sensitive
antigen detection method that utilises polymerase chain reaction
(PCR) from a secondary antibody-target DNA conjugate to detect
the specific binding ofaprimary antibody toits antigen. The univer-
sality of a single protocol for immuno-PCR has not yet been
confirmed. To examine this and assess the utility of immuno-PCR
for detection of very low levels ofDNA adducts in human tissues,
we established the method using purified rabbit polyclonal anti-
bodies recognising four biochemically diverse antigens: pyruvate
dehydrogenase complex (PDC; oligomeric; Mr 8.5 x 106), the DNA
repair enzyme 06-methylguanine-DNA methyltransferase (MGMT;
monomeric; M 21 700), an oligopeptide (20-mer; Mr 2310) and a
DNA adduct conjugated to BSA (06-methylguanosine-BSA; Mr
67 600). Antigen detection limits by immuno-PCR were:
- 3 x 10-4
amol or 180 molecules of 06-methylguanosine, - 6 x 10A amol or
350 molecules of PDC,
- 0.2 amol or 1.3 x 105 molecules of
oligopeptide, and - 115 amol or 700 x 105 molecules of MGMT.
Antigen instability was observed with MGMT in highly dilute solu-
tion, which may account in part for the lower detection limit.
Results ofthis study indicate that (i) immuno-PCR is able tobe used
for the ultrasensitive detection of a diverse variety of antigens, (ii)
increases in immuno-PCR detection limit are reflected by increases
in primary antibody titres determined by ELISA, and (iii) the sensi-
tivity ofdetection using immuno-PCR is independent ofantigen Mr.
We have yet to investigate the suitability ofthe method fordetecting
anything other than purified antigens. Nevertheless, our findings
suggest that immuno-PCR may be of use for the highly sensitive
detection ofavariety ofrare cancer-associated antigens (e.g. tumour
markers and those of metastatic/residual disease) in complex
mixtures and/or antigens contained in small tissue specimens.
Expression of the cytoplasmic proteins
a-catenin and ,-catenin in primary and
metastatic colorectal cancer: evidence of
altered cellular adhesion
TJ Hugh, GJ Poston andAR Kinsella
Cellular Oncology Group, Department of Surgery, University of Liverpool,
Liverpool L69 3BX, UK
The E-cadherin cell adhesion complex plays a fundamental role in
maintaining the epithelial cell phenotype and has been shown to
function as a tumour suppressor, in vitro. E-cadherin is a trans-
membrane glycoprotein which associates with several cytoplasmic
molecules, including a-catenin and f-catenin. Binding of E-
cadherin to the catenins is essential for normal function of the
complex and may serve to link it to the actin cytoskeleton.
Reduced expression of E-cadherin and a-catenin have been
shown to correlate with de-differentiation and metastatic potential
in several human tumours. However, the role of P-catenin in
tumours is less clear as it may be involved in cellular signalling in
addition to its role in cell adhesion. Reduced expression of cell
adhesion molecules in metastases has also been reported. The aim
of this study was to document the expression ofa-catenin and 3-
catenin in a large series of colorectal tumours and their corre-
sponding liver metastases.
Immunohistochemical analysis using monoclonal antibodies
was performed on paraffin and frozen sections of47 specimens of
primary adenocarcinomas of the colon and rectum and their
corresponding liver metastases.
Only 9/47 (19%) primary tumours and 5/47 (11%) secondary
tumours had normal membranous expression of ax-catenin. In
these cases expression was localised to the apicolateral region of
the cell membrane. In 25/47 (53%) primary tumours and 16/47
(34%) secondary tumours cytoplasmic and strong membranous
expression of a-catenin were seen together. These sections were
scored as abnormal but different from sections with weak orabsent
expression of a-catenin. The proportion of secondary tumours
with weak or absent ax-catenin expression was significantly less
than in theprimary tumours (Wilcoxin matched-pairs signed-ranks
test, P < 0.05). There was no apparent association between the
differentiation status or Duke's stage of the primary tumour and
expression ofa-catenin.
With regard to [B-catenin, 39/47 (83%) primary tumours and all
ofthe liver metastases displayed abnormal expression, often with a
characteristically intense staining pattern throughout the cyto-
plasm as well as along the cell-cell boundaries. Intensity of
expression of 3-catenin was most marked at 'proliferating fronts'
of tumour growth and, in general, these areas of cytoplasmic
staining corresponded with reduced membranous staining. There
was no association between differentiation status or Duke's stage
and expression of 3-catenin in the primary tumour. Also, no corre-
lation was found between expression of a-catenin or ,B-catenin in
the primary tumours and overall survival.
Conclusions: Approximately 80% ofprimary colorectal cancers
display abnormalexpression ofa-catenin and f-catenin and expres-
sion ofthese molecules in liver metastases is even less marked. This
suggests that cellular adhesion is not re-established in metastatic
tumours. The results of this study are currently being compared to
another series ofunselected patients with colorectal cancer.
Regulation of tumour associated
macrophage MMP-9 production by a TNF-oa
loop and a matrix metalloprotease inhibitor
TMLeberand FR Balkwill
Imperial Cancer Research Fund London, 44 Lincoln's Inn Fields,
London WC2A 3PX
The matrix metalloprotease MMP-9 (gelatinase B) localises to
tumour associated macrophages in ovarian cancer, but the signals
within the tumour leading to its production are not defined. Co-
culture ofovarian cancer cells (PEO-1) and the monocytic cell line
(THP-1) led to production of the 92 kDa form of MMP-9.
Conditioned medium (CM) derived from PEO-1 also stimulated
monocytic cells to produce MMP-9 but not vice versa. There was
evidence that TNF-a was involved in tumour stimulated monocyte
MMP-9 production: antibody to TNF-a inhibited MMP-9 produc-
tion in the co-cultures and by CM treated monocytes. In addition,
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the synthetic matrix metaloprotease inhibitor (MMPI) BB-2116,
which also blocks TNF-a shedding, inhibited MMP-9 release in the
co-cultures, and, at the same IC50, from CM stimulated monocytic
cells. However, two different experiments suggested that the stimu-
lating factorpresent in CM was notTNF-a. We suggestthatovarian
cancer cells can stimulate monocytic cells to make MMP-9 via a so
far unidentified factor and that this release is dependent on a mono-
cytic autocrine TNF-a loop on the monocytic cells. Synthetic
MMPIs may indirectly inhibit protease production by preventing
autocrine orparacrine cytokine release. This may contribute to their
actions in models ofcancer and inflammatory disease.
Induction of spheroid formation in breast
cancer cell lines by antibody 17E6 requires
not only functional E-cadherin but also both
inhibition and crosslinking of axv integrins
John FMarshall, Philip Perryand Ian R Hart
Richard Dimbleby/ICRF Department of Cancer Research, St Thomas's
Hospt., London SE1 7EH, UK
We areinvestigating theroleofavintegrins inthegrowth andbehav-
iour ofbreast carcinoma cells. Less than 1 gg/ml ofthe av-blocking
antibody 17E6 (supplied by S. Goodman, E. Merck) induces forma-
tion of multicellular spheroids from monolayers of the breast cell
lines ZR75-1, BT474 and T47D, all ofwhich express functional E-
cadherin. In contrast, 5 ,ug/ml of 17E6 has little effect on the breast
lines MCF7, MDAMB 231, MDAMB 468, SkBr3 and BT20, all of
which lack functional E-cadherin. Pre-treatment of ZR75-1 cells
with the E-cadherin blocking antibody DECMA-1 inhibited the
spheroid-inducing effects of 17E6. These data show that functional
E-cadherin is required for spheroid formation and suggest that there
may be 'cross-talk' between E-cadherin andintegrins. Monolayers of
ZR75-1 cells did not form spheroids in response to whole IgG ofthe
non-blocking anti-av antibodies 13C2 orP2W7, but did form spher-
oids in response to bivalent F(ab)2 fragments of 17E6. Monovalent
F(ab) fragments of 17E6 were unable to induce spheroid formation
unless goat anti-mouse antiserum was also present. As both 17E6
F(ab)2 and 17E6 F(ab) fragments block av these data suggest that
neither blocking av norav-crosslinking alone is sufficient for 17E6-
induction of spheroids and that both events are required. Moreover,
since integrin-crosslinking is associated with optimal integrin
signalling these data indicate that integrin-mediated signalling may
have profound effects on the morphogenesis ofbreast cancer cells.
Retroviral transfer of the integrin P3 cDNA
into P3 negative human melanoma cells
H Cadiou, JFMarshall, IR Hart
Richard Dimbleby Department of Cancer Research, Imperial Cancer
Research Fund Laboratory, St Thomas's Hospital, London SE1 7EH
The av,3 integrin is a cell surface adhesion glycoprotein thought to
be involved in the migration and metastasis ofmalignant melanoma
cells. The mechanistic basis of this involvement has not been fully
defined. To clarify the role ofav[3 in the invasive and malignant
behaviour ofmelanoma we have carried out aP3 transfection study.
Two av,3-negative human occular melanoma cell lines, VUP and
OM431 (expressing av1 I andavP5), were infected with aretrovirus
containing the full-length ,3 cDNA under the transcriptional control
of the strong viral LTR promoter. As controls, retroviruses lacking
the gene or containing a mutant, non-functional ,3 integrin were
employedc Puromycin-resistant colonies were selected and [3-
expressing clones were isolated by Dynabead sorting using the
anti-[3 monoclonal antibody SZ.21. FACS analysis with the
heterodimer-specific antibodies LM609 and 23C6 verified cell
surface expression of av,B3. Immunoprecipitation with the LM609
antibody confirmed de novo expression ofav[B3 heterodimers in the
infected cells. Unexpectedly the monomer 33 seemed to show a
greater affinity for axv than did J1 as indicated by the reduction in or
lack of detectable av1l by immunoprecipitation observed in both
VUP and OM431 infected cells. These data are consistent with the
possibility that avP3 expression in the later stages of melanoma
development is aconsequence ofthe 'switching on' ofP3 expression
and the preferential formation ofavP3 heterodimers.
Evidence for a tumour suppressor gene on
distal chromosome 17q with early effects in
ovarian cancer
I Hickey1, S Mcllroy1, AN Cranston', J McCormick1,
P Harkin', RJAtkinson2, J Weissenbach3, EJStanbridge4
and SEH RusselF
'School of Biology and Biochemistry, and 2School of Clinical Medicine,
Queen's University, Belfast, N. Ireland, 3Genethon, Every, France,
4University of California, Irvine, USA
We have analysed abank of75 sporadic epithelial ovarian tumours
including 16 benign samples for loss of heterozygosity at 20 loci
on chromosome 17. The majority of malignant tumours showed
extensive loss involving the whole chromosome or at least the
entire long arm. However, a sub-set of tumours showed distinct
regions of interstitial loss. Although some examples of partial
deletions were found on the short arm, most involved the long
arm. A common region of deletion spanning less than 1 cM lying
between D17S939 and D17S937 was observed in eight tumours.
These included examples ofall the majorhistopathological classes
ofovarian tumours, serious, endometrioid and mucinous.
Significantly this group included two benign tumours and one
borderline tumour. This indicates that loss from this region may
represent an early event in the development of epithelial ovarian
tumours, which is often masked by subsequent losses from other
regions of this chromosome. This common region of deletion is
clearly distal to BRCAI, and FISH analysis using YACs identified
as carrying microsatellites mapping to the region indicates a loca-
tion close to the telomere.
We have also attempted to find functional evidence for the pres-
ence ofatumour suppressor gene by using microcell fusion to intro-
duce a normal copy ofchromosome 17 into ovarian cell lines. Two
cell lines, A2780 and OAW42 were used. In both cases clones of
hybrid cells were formed which ceased growth within seven weeks
afterfusion. We have excludedp53 as being thegeneresponsible for
this growth suppression, but we have not yet mapped the gene
responsible to a specific region ofthe chromosome.
In conclusion we have produced evidence for a specific region
ofloss ofheterozygosity in ovarian tumours which can be detected
at early stages, and the presence of a gene on the same chromo-
some which is responsible for regulation of immortalisation of
ovarian epithelium.
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MAGE gene expression in benign and
malignant ovarian tissue
AM Gillespie', S Rodgers1, AP Wilson2 and RC Rees3
'YCRC Inst. Cancer Studies and Dept. Clinical Oncology, University of
Sheffield, Sheffield S10 2RX, 2Oncology Research Lab., Derby City Gen.
Hospital, Derby DE22 3NE, 3Dept. Life Sciences, Nottingham Trent
University, Nottingham Nil 8NF
In the UK ovarian cancer is the most common gynaecological
malignancy. Due to the nature of the condition and the limitations
ofcurrent therapy, prognosis is poor with an overall 5 year survival
of only 30%. New treatment modalities may, in future, contribute
to an improved outlook for women diagnosed with this disease.
One such therapy may be Antigen Specific Immunotherapy with
MAGE peptide products. It is known that MAGE 1-4, 6 & 12
genes are expressed in some human cancers,' but not normal tissues
with the exception of the testes and placenta. MAGE 1 & 3 are
targets for specific immunotherapy as they encode peptide antigens
- 'tumour antigens' - which are presented in association with HLA
class 1 molecules and are recognised by cytotoxic T lymphocytes.
To determine if ovarian cancer patients would be suitable for
MAGE-peptide vaccine based immunotherapy, the frequency of
MAGE 1-4 genes expression in ovarian tumours was assessed
using Reverse Transcription Polymerase Chain Reaction (RT-
PCR) and product verification with digoxigenin-labelled oligonu-
cleotide probes specific for each MAGE gene.
In this preliminary study 12/20 ovarian cancer specimens
studied expressed MAGE 1, including 8/9 serous adenocarci-
nomas. In addition 13/19 benign pathological ovarian lesions
studied also expressed MAGE 1, including simple cysts, cystade-
nomas and adenofibromas. No MAGE expression was detected in
5 normal ovarian specimens.
Ifthe frequency ofMAGE 1 expression in serious cystadenocar-
cinomas is confirmed in this ongoing study, patients with this
condition will be candidates for MAGE-peptide immunotherapy.
It has previously been asserted that MAGE gene expression is a
relatively late event in the neoplastic transformation of cells.2 Our
initial findings suggest that MAGE 1 is expressed in non-malig-
nant ovarian tissue. Further exploration of MAGE expression in
benign and malignant ovarian tumours may shed new light on the
poorly understood natural history ofovarian carcinoma.
REFERENCES
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A quantitative assessment of the leukocyte
infiltrate in ovarian cancer and its
relationship to the expression of c-c
chemokines
RPMNegus1, GWH Stamp2, J Hadley3 and FR BalkwillI
'Imperial Cancer Research Fund, London WC2A 3PX, 2Hammersmith
Hospital, London W12 OHS, 31CRF, Oxford OX3 7LF
We have defined the host leukocyte infiltrate in epithelial ovarian
tumours and related this to the expression of c-c chemokines.
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Immunohistochemical analysis of 20 paraffin embedded biopsies
showed that the infiltrate was primarily composed of CD68+
macrophages and CD8+/CD45RO+ T-cells (median values 3700
cells/mm3 and 2200 cells/mm3 respectively). Natural killer cell, B-
cells, and mast cells occurred in lower numbers (median values
0-200 cells/mm3). Eosinophils were rarely seen and neutrophils
weremainly confined to blood vessels. Moreinfiltrating cells were
found in stromal than in tumour areas. Only macrophages occurred
in significant numbers in areas of necrosis (P < 0.0005). Using in
situ hybridisation to mRNA we examined expression of the
chemokines MCP-1, MIP-la, MIP-lI3 and RANTES. MCP-l and
MIP-la were expressed by significantly more cells than MIP-1[
and RANTES (P <0.005). In tumourepithelial areas, the predomi-
nant chemokine was MCP-1. MCP-l and MIP-la were the
predominant stromal chemokines. A significant correlation was
found between the total number ofCD68+ macrophages or CD8+
T-cells and the number of cells expressing MCP-l (rS = 0.50, P =
0.026 and rs = 0.63, P = 0.003 respectively) and also between the
CD8+ population and RANTES expressing cells (rs = 0.6, P =
0.003). We suggest thatMCP-1 islargelyresponsible forthe leuko-
cyte infiltrate in ovarian carcinomas, but the expression of other
chemokines may determine its exact nature. We have begun to
examine the factors that may be responsible for the expression of
MCP-l in these tumours. Using RT-PCR andNorthem analysis, we
have found thatTNF-cx stimulated tumour cell expression ofMCP-
1. Maximal expression was at about 3 hours, with levels falling
over 24 hours. Since TNF-a is expressed by both tumour cells and
tumour associated macrophages and can stimulate MCP-1 expres-
sion in a variety of cell types, this cytokine provides one possible
link between the infiltrating cell population and the pattern of
expression ofchemokines observed within ovarian carcinomas.
Mismatch repair deficiency and cisplatin
resistance in ovarian cancer
AAnthoney', A Mcllwrathl, A van derZee2, G Hirst',
R Brown'
1CRC Dept. of Medical Oncology, CRC Beatson Laboratories, Garscube
Estate, Glasgow G61 1BD. 2Dept. Gynecologic. Oncology, University
Hospital, Groningen, The Netherlands
We have previously shown that nine of ten independent cisplatin
resistant derivatives of an ovarian carcinoma cell line possess a
microsatellite instability phenotype.' The lines also display cross-
resistance to the methylating agent methylnitrosourea (MNU) after
inhibition ofalkyltransferase activity withO6benzylguanine. Two of
these lines have subsequently been shown to be defective in strand
specific mismatchrepairofsingle base anddinucleotidemismatches
using an in vitro mismatch repair assay.2 Complementation of cell
extracts with purified mismatch repair proteins identified hMutLa
as the defective component ofmismatchrepair in these lines.
To further define the defect in mismatch repair in the set of ten
cisplatin resistant cell lines we have determined the levels of the
fourmajor mismatchrepairproteins. Using aWestern immunoblot
assay no significant variation in the levels of hMSH2 or GTBP
(hMSH6) were observed amongst the cell lines or when compared
to the parental line. However, no hMLHl or hPMS2 protein was
detectable in nine ofthe resistant cell lines.Immunohistochemistry
confirmed the absence ofhMLHl and hPMS2 protein expression
in the resistant derivatives compared to parental cells. RT-PCR
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was used to assess mRNA expression from the mismatch repair
genes. By this method levels of hMSH2 and hPMS2 mRNA were
similar in all lines. One of the cisplatin resistant lines showed
similar levels ofhMLH1 mRNA to parental cells whilst in another
the levels, although detectable, were greatly reduced. No hMLH1
mRNA was detectable in any of the other 8 cisplatin resistant
lines. Southern analysis ofthe hMLH1 gene between parental and
resistant lines revealed no gross rearrangement to explain the lack
ofhMLHI expression. In conclusion, lack ofhMLH1 gene expres-
sion is the basis for the defective mismatch repair in a series of
cisplatin resistant ovarian carcinoma cell lines.
We have, in addition, observed loss of hMLH1 expression in
10% (4/41) of untreated ovarian tumours and 30% (4/12) of
residual tumour removed at second look surgery after platinum
based chemotherapy. This more frequent loss of hMLH1 post
chemotherapy is statistically significant (P < 0.05). No difference
was observed for hPMS2, hMSH2 or GTBP.
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